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ABSTRACT
Adriamycin is an important anticancer agent. However, the clinical use of
Adriamycin is limited by its undesirable side effects, especially cardiotoxicity. One of
the most likely mechanisms of Adriamycin toxicity is the production of reactive oxygen
free radicals. Catalase is a major enzyme involved in detoxification of hydrogen peroxide
(H20 2) in mammalian cells. It has been shown that catalase activity per g tissue of the
heart is very low in comparison to other tissues, being only about 2% that of liver in the
mouse. This less proficient ability to dispose of reactive oxygen species may be
responsible for the high sensitivity of the heart to Adriamycin toxicity. This dissertation
research was thus designed to test this hypothesis.
Transgenic technique was applied to produce cardiac catalase overexpressing
transgenic mice. A transgene for overexpression of catalase in the heart was constructed.
This transgene contained the alpha cardiac myosin heavy chain promoter, the rat catalase
cDNA, and polyadenylational sequence. This transgene was modified and injected into
mouse embryos. The embryos were implanted into pseudopregnant females and allowed
to come to term. The transgenic mice were identified using Southern blot, Dot blot, and
polymerase chain reaction (PCR) procedures. Catalase activities and mRNA
concentrations in the heart and other organs were measured. Fifteen healthy transgenic
mouse lines were produced.

xm

Catalase activity was overexpressed specifically in the heart, ranging from 2- to
630-fold higher than normal. Other antioxidant systems were not altered in the transgenic
heart. The transgenic mice were used to determine the effect of catalase activity on acute
and chronic cardiotoxicities of Adriamycin. In the acute studies, the isolated mouse atria
were incubated with Adriamycin and changes in contractile force and heart rate were
recorded as a measurement of cardiotoxicity. Changes of cardiac lipid peroxidation and
serum creatine phosphokinase (CPK) activity in the mice treated with Adriamycin at 20
mg/kg body weight were also measured. In the chronic studies, both transgenic mice and
controls were repeatedly treated with low doses of Adriamycin. Myocardial
morphological changes were measured. As compared to normal controls, transgenic
lines expressing catalase activity 60- or 100-fold higher than normal exhibited dramatic
resistance to Adriamycin-induced cardiac lipid peroxidation, elevation of serum creatine
phosphokinase, and functional changes in the isolated atrium. The transgenic mice were
also highly resistant to cardiotoxicity induced by chronic treatment of Adriamycin. In
addition, catalase overexpression suppressed hypoxia-reoxygenation induced decrease in
cardiac contractile force and contraction rate, and morphological alterations. The results
demonstrate that catalase overexpression in the heart provides protection against cardiac
oxidative damages.

xiv

CHAPTER I
INTRODUCTION
Adriamycin-induced cardiotoxicity is a major limiting factor for clinical
application of this agent. A proposed mechanism for the cytotoxic effect of Adriamycin
is the production of reactive oxygen species during its intracellular metabolism.
Although a number of studies have suggested that a relative lack of antioxidant defense,
in particular low catalase activity in the heart, may be involved in the development of
cardiotoxicity of Adriamycin, current approaches have not been able to provide complete
understanding the relationship between low antioxidant capacity in the heart and
Adriamycin cardiotoxicity. This chapter focuses on the relevant literature pertaining to
Adriamycin and its cardiotoxicity, catalase and its physiological function, and the role of
catalase in cardioprotection against oxidative damage.
Adriamycin (Doxorubicin)
Structure. Action, and Toxicity
In 1969, the anthracycline antibiotic Adriamycin was originally isolated from the
fungus streptomyces pencetius (1). The anthracycline antibiotic has a tetracycline ring
structure with an unusual sugar, daunosamine, attached by glycoside linkage (Fig. 1).
The quinone and hydroquinone moieties on adjacent rings function as electron-accepting

1

2

Fig. 1. The chemical structure of Adriamycin. Chemically, Adriamycin consists of a
water-insoluble tetracycline aglycone (structure A B C D) and a water-soluble reducing
daunosamine sugar. Several parts of the molecule can be involved in the metabolism of
Adriamycin. Ring C is a quinone group which can be activated into a semiquinone
radical after one-electron reduction. Ring B is a hydroquinone which can also be
activated into a semiquinone radical after one-electron-oxidation. The C9 side chain is
probably important in the iron-catalyzed autoxidation of the molecule. Difference in the
C9 side chain form the only difference between Adriamycin and its analog daunorubicin.

3
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and -donating agents and can be activated into a semiquinone radical which is associated
with the cytotoxicity of the drug.
Since the formulated compound was first made available for clinical use in the
early 1970's, more than two million patients have received this medication. Adriamycin
is presently a well established drug and a major therapeutic agent in the treatment of
cancer. It is used extensively as part of combination chemotherapy regimens for the
effective treatment of acute non-lymphocytic leukemia, Hodgkin’s and non-Hodgkin’s
lymphomas, breast cancer and sarcomas (2,3). It has exhibited clinical utility in the
treatment of human solid tumors including those of breast, lung, ovary, head and neck,
endometrium, prostate, and bladder. It is also active against neuroblastoma,
osteosarcoma, Ewing’s tumor, and rhabdomyosarcoma.
The acute toxic effects of Adriamycin may not relate to dose, but the chronic toxic
effects of Adriamycin are dose related. Nausea and vomiting occur in more than 50% of
patients receiving Adriamycin while some degree of alopecia is seen in all patients (5).
Somnolence may occur during the first 24 hr after injection, and lethargy lasting for
several days is often seen in the elderly. The dose-limiting toxicities of the anthracycline
antibiotic are myelosuppression, mucositis, and cardiomyopathy.
Mechanism of Action and Toxicity
The mechanism of the antitumor activity of Adriamycin is not completely
understood. A number of mechanisms have been proposed including intercalation of the
anthracycline aglycone moiety between adjacent base pairs in the DNA double helix
producing inhibition of DNA, RNA, and protein synthesis (4,5), inhibition of proteins
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associated with DNA strand breaks due to anthracycline-induced stabilization of the
topoisomerase II-DNA complex with the DNA in the open conformation (6,7), and
alteration of cell membrane function (8-10). Another mechanism for the cytotoxicity of
Adriamycin is anthracycline free radical mediated alkylation and DNA degradation (1113). However, none of these mechanisms alone appears adequate to explain all of the
cytotoxic properties of Adriamycin (14,15). It is probable that the mechanism of
antitumor activity of Adriamycin differs from that by which cardiac toxicity occurs, since
a number of animal and clinical studies have shown that by altering the schedule of
administration or by using protective agents it is possible to decrease the cardiotoxicity
without reducing the antitumor effects of Adriamycin (16-19). Nausea and vomiting due
to Adriamycin can be reduced by decreasing the peak plasma concentration of the drug
(20). Myelosuppression, mucositis and alopecia appear from clinical studies to share a
similar mechanisms of action to antitumor activity.
Cardiotoxicity
Cardiotoxicity is the most prominent adverse effect of Adriamycin. Acute
cardiovascular effects of Adriamycin can develop within minutes but usually within a few
hours of Adriamycin administration. Electrocardiographic studies show an incidence of
abnormalities in up to 41% of patients receiving Adriamycin (21-24). The ECG effects
include nonspecific S-T wave changes, sinus tachycardia, premature ventricular and atrial
contractions, and low voltage of the QRS complex. These ECG changes are reversible in
a few days to two months and do not appear to be associated with the development of
Adriamycin cardiomyopathy. A change in myocyte morphology has been consistently
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observed. This change occurs within 10 min after administration of a single large dose of
Adriamycin and returns to normal within 14 hours (25). These acute toxic effects are not
dose-dependent and do not contraindicate further therapeutic application of the drug (26).
In contrast to the acute toxic effects, chronic cardiomyopathy induced by
Adriamycin is the major drawback of the drug in cancer chemotherapy. Congestive
cardiomyopathy is the cumulative dose-related toxicity of Adriamycin therapy and is
proportional to the dose of Adriamycin administered (27,28). A total dose of 500-555
mg/m2 has been shown in patients with no underlying cardiac disease and a total dose of
450 mg/m2 has been recommended in patients receiving combined methods of therapy.
Individual patients may tolerate higher total Adriamycin doses than the recommended
maximum but the risk is considerable. The clinical presentation of patients with
Adriamycin induced cardiomyopathy is non-specific. The first sign may be tachycardia
with the patient complaining of shortness of breath or a nonproductive cough, and the
usual signs of congestive failure include distended neck veins, gallop rhythm, ankle
edema, hepatomegaly, cardiomegaly, and pleural effusion (29-31). The onset of
symptoms generally occurs about one month after the first dose of Adriamycin but can
vary from hours to as long as eight months (32). The primary cardiac morphologic
changes observed in patients include loss of myofribris, cytoplasmic vacuolization due to
swelling of the sarcotubular system, swollen mitochondria, enlarged nuclei with a large
distinct nucleolus, increased numbers of lysosomes, and lipid accumulation (33-36).
Percutaneous endomyocardial biopsies in patients have demonstrated a direct relationship
between the total dose of Adriamycin and pathologic changes in the myocardium (37-39).

7

Similar structural changes of Adriamycin cardiomyopathy have been seen in a variety of
experimental animals (40-42). Although these morphological and functional descriptions
of Adriamycin’s cardiotoxicity have been known for several years, the mechanism of
production of these lesions and the reason for the selective toxicity to the heart remain
unknown.
Free Radical Formation and Adriamycin Cardiotoxicity
Free Radical Formation bv Adriamycin
Free radicals are chemical species that contain an electron with unpaired spin.
This electronic phenomenon makes many free radicals very unstable and short-lived and
capable of non-enzymatic oxidation of macromolecules including enzymes and other
membrane and cytosol components (43,44). Biologically, unrestrained free radical
production can lead to cell damage and death.
Hando and Sato first showed that the metabolism of Adriamycin and other
quinone-containing compound could lead to free radical generation in a microsomal
NADPFI-oxidase system (45). They found that reactive semiquinone free radicals were
formed and reacted with molecular oxygen to produce the reactive superoxide anion (0 2‘
•). Two years later, Goodman and Hochstein showed that NADPH and purified
cytochrome P450 reductase in the presence of Adriamycin consumed more oxygen from
the media than predicted from the amount of drug presented (46). They postulated a
reduction-autoxidation cycle for Adriamycin. In this way one molecule of Adriamycin
could form many molecules of oxygen centered free radicals by cycling from a quinone
to semiquinone then back to quinone following the reduction of molecular oxygen to
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superoxide anion. The superoxide anion generated by redox cycling of Adriamycin may
initiate lipid peroxidation or be dismutated via superoxide dismutase to hydrogen
peroxide. Free radicals, hydrogen peroxide and superoxide anion can damage membranes
and macromolecules and cause cell damage. Hydrogen peroxide gives rise, by an iron
catalyzed reaction to hydroxyl radicals that may react with: (a) unsaturated lipids causing
lipid peroxidation and destruction (47,48); (b) cellular DNA, thereby inducing DNA
damages (49-51); or (c) deoxyribose causing deoxyribose breakdown and degradation
(52,53). Hydroxyl radicals can also be formed by the reaction of Adriamycin
semiquinone radical with hydrogen peroxide (54,55). But the reaction of Adriamycin
semiquinone radical with hydrogen peroxide can not effectively compete with the
reaction of oxygen with Adriamycin semiquinone radical to form superoxide anion
radical. A summary of the pathways for formation of oxygen radicals by redox
cycling of Adriamycin is shown in Fig. 2.
Free Radical Chemistry of Adriamycin in Cardiac Tissue
Free radical production in cardiac cells due to one-electron-reduction of
Adriamycin might occur at the nuclear envelope, in mitochondria, cytosol, or
sarcoplasmic reticulum (56,57). The major site of Adriamycin-induced oxygen radical
formation in the heart is complex I of the mitochondrial electron transport chain, probably
the NADPH dehydrogenase (58,59). Heart muscle cells are extremely rich in
mitochondria, which might render them particularly vulnerable to free radicals generated
at these organelles. The major oxygen species formed by redox cycling of Adriamycin in
the heart is hydroxyl radical (60). Using ESR and spin trapping with DMPO, Thomalley
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Fig. 2. Formation of oxygen radicals by redox cycling of Adriamycin. Adriamycin can
be reduced by cellular flavoproteins to form its one-electron reduced semiquinone form.
In the presence of oxygen the semiquinone free radical is oxidized back into the parental
quinone form under formation of superoxide radicals. In the absence of oxygen the
semiquinone is unstable, it loses its sugar moiety and an intermediate C7 free radical can
be formed. This radical can bind covalently to cellular macromolecules
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and Dodd found only hydroxyl radical and no superoxide anion radical formed in rat
heart sarcosomas incubated with NADPH and Adriamycin (61). Hydroxyl radical
formation was inhibited by catalase but not by superoxide dismutase, suggesting a direct
reduction of hydrogen peroxide to hydroxyl radical. Nohl and Jordan also found no ESR
evidence for formation of superoxide anion radical by respiring rat heart mitochondria
and Adriamycin using DMPO as a spin trap (62). In this study, an Adriamycin-derived
semiquinone radical signal was seen which was stable even in the presence of oxygen.
The signal disappeared on addition of hydrogen peroxide and concomitantly there
appeared a DMPO-hydroxyl radical adduct signal. These results have been interpreted to
indicate that an Adriamycin semiquinone radical was produced during mitochondrial
respiration, probably at the lipophilic phase of the mitochondrial inner membrane, in a
way which precluded electron transfer to oxygen. This allowed reaction at the
anthracycline semiquinone radical with hydrogen peroxide, probably present at relatively
high concentrations in the heart because of low levels of catalase, to form hydroxyl
radical (63).
Free Radical- Induced Cardiac Dysfunction
Calcium released from sarcoplasmic reticulum (SR) appears to be involved in
redox cycling of sulfhydryl groups of terminal cistemae . Peroxides and oxidizing agents
promote rapid release of calcium from SR. Calcium sequestration was inhibited by 70%
in rat cardiac SR preincubated for 30 min with Adriamycin (64,65). This inhibition was
attenuated by incubation with catalase and the free radical scavengers, N-acetylcysteine
and glutathione (66). Thus, free radicals may promote extensive calcium release and
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depletion of SR calcium stores, leading to impaired contractility and impaired cardiac
relaxation. Free radical-induced cardiac dysfunction may also reflect mitochondrial
injury. Substantial amounts of superoxide anion are formed when Adriamycin and
NADH are added to the mitochondrial fraction of rat heart (57). Lipid peroxidation is
another mechanism that leads to oxidative damage. The reactive oxygen species may
react with cellular molecules such as lipids to generate lipid peroxidation in the plasma
membrane and cause lethal membrane damage.
Free Radical Mechanism of Adriamvcin-induced Cardiotoxicitv
The cardiotoxicity of Adriamycin has frequently been linked to the formation of
reactive oxygen species (47,58,67-68). Support for the concept that Adriamycin produces
its cardiotoxicity through an oxidative mechanism comes from several laboratories.
Olson et al. showed that although Adriamycin lowers glutathione (GSH) levels in heart,
liver, and red blood cells of mice, the lowest value in liver was still eight times greater
than the corresponding value for GSH in the heart. Olson further showed that if cardiac
GSH was depleted by diethyl maleate prior to Adriamycin administration, significant
potentiation of acute Adriamycin-induced lethality occurred. Conversely, the acute
lethality and cardiac lesions produced by Adriamycin could be prevented by prior
administration of sulfhydryl donors that also prevented the Adriamycin-induced fall in
myocardial GSH concentrations (69,70). Another study showed that mice pretreated with
N-acetylcysteine survived for a significantly longer time than those receiving Adriamycin
alone and that pretreatment with N-acetylcysteine prevented the ultrastructural cardiac
lesions associated with acute Adriamycin administration (71). Sulfhydryl donors such as
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cysteamine and N-acetylcysteine are very reactive toward free radicals through nonenzymatic donation of hydrogen atoms (72). Thus, exogenously administered sulfhydryl
donors are preferentially oxidized by oxygen centered free radicals, thereby protecting the
tissue from oxidative damage. Another study showed that when mice were placed on a
selenium-free diet to reduce endogenous glutathione peroxidase activity (selenium being
a required cofactor for glutathione peroxidase), the mortality produced by acute
Adriamycin administration doubled (73). Myers et al. found that the antioxidant vitamin
E significantly protected mice from acute Adriamycin-induced cardiotoxicity (74). These
studies suggest that Adriamycin produces toxicity through an oxidation mechanism.
Further evidence that links Adriamycin-cardiotoxicity to oxygen radical formation
is the finding that newer, less cardiotoxic anthracyclines undergo less redox cycling than
Adriamycin. Studies by Lown et al. have shown a positive correlation between the
electrochemical generation of oxygen species from a series of anthracyclines and their
cardiotoxicity in the rat. 5-Iminodaunorubicin which is less cardiotoxic in animals than
either daunorubicin or Adriamycin does not undergo enzymatic reduction to form an
anthracycline semiquinone radical (60,68,75-77). 4'-Deoxydoxorubicin and 4demethoxydaunorubicin, which in experimental animals are less cardiotoxic than
doxorubicin or daunorubicin, do not generate oxygen free radicals spontaneously in
aerated aqueous solution, unlike the parent anthracycline (78,79). Both compounds are,
however, equally active as doxorubicin in stimulating oxygen use when incubated with
rat liver microsomes and NADPH.

14

Lipid peroxidation is an important indicator of oxidative damage. Unsaturated
fatty acids are peroxidized when exposed to hydroxyl radicals in the presence of a metal
catalyst (80). This process might damage cellular membranes and eventually kill cells. A
number of studies indicated that Adriamycin increased lipid peroxidation in intact cardiac
tissues and organelle preparation (47,81-83). In the presence of oxygen, Adriamycindependent lipid peroxidation is generally inhibited by superoxide dismutase, catalase,
glutathione, iron chelators, and hydroxyl radical scavengers (82-84). Studies with rat
heart microsomes and NADPH have shown that Adriamycin stimulates lipid
peroxidation, but only if the microsomes are prepared from rats fed a diet deficient in atocopherol (85,86). Mouse heart microsomes, which have low endogenous levels of atocopherol, exhibit a marked increase in lipid peroxidation in the presence of Adriamycin
(66,84). 4'-Epidoxorubicin, which is less cardiotoxic than Adriamycin in mice, does not
increase lipid peroxidation measured by malondialdehyde formation in mouse heart in
vivo (87). Studies using breath ethane expiration, which is generally considered as a
more reliable indicator of lipid peroxidation in vivo, have failed to show an increase in
lipid peroxidation in rats given lethal doses of Adriamycin (88). However, several
compounds that are believed to exert their toxic effects through generation of active
oxygen species and lipid peroxidation, for example nitrofurantoin, paraquat, diquat, and
menadione, also did not increase ethane production in vivo in this system (89). Thus, the
failure to demonstrate an Adriamycin-dependent increase in ethane production in intact
animals can not be taken as conclusive evidence for a lack of lipid peroxidation in the
heart in vivo.
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In summary, the available data suggest that Adriamycin produces its
cardiotoxicity through an oxidative free radical mechanism. However, the free radical
hypothesis has serious limitations. For example, at cardiotoxic concentration Adriamycin
often fail to generate free radicals or produce evidence of oxidative stress (90-92). In
addition, free radical scavengers often fail to prevent Adriamycin cardiotoxicity (93-95).
Therefore, the free radical mechanism of Adriamycin-induced cardiotoxicity needs to be
further studied.
Catalase
History and Structure of Catalase
Catalase is widely distributed in a variety of life forms and has been studied in
great detail (96-99). In 1818 Thenard observed that hydrogen peroxide was decomposed
by animal tissues with the liberation of gaseous oxygen: 2H20 2 - 2H20 + 0 2. Eightythree year later, in 1901, Loew (100) demonstrated that this effect was due to a specific
enzyme which he named catalase. In 1923, Warburg (100) suggested that catalase was an
iron-containing enzyme because it was inhibited by cyanide. Evidence that its prosthetic
group was hematin was provided by Zeile and Hellstrom in 1930 (100). The enzyme was
first crystallized from beef liver by Summer and Dounce in 1937 (101). It has since been
crystallized from liver and erythrocytes of a number of animal species, including the
human (100). It has also been crystallized from bacteria (102). The primary structure of
beef liver catalase has been established but the complete sequence of human catalase is
not yet known. Chemical analyses have confirmed that the native enzyme has a
molecular weight of 240,000 daltons, and possesses four subunits of the same size and
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amino acid sequence (103-105). Each subunit has an apparent molecular weight of about
60,000 and contains one ferriprotoporphyrin (hematin) group. Genetic studies, utilizing
the inborn error “acatalasemia” in humans and mice have indicated that a single
structural gene is responsible for the total synthesis of the enzyme (106,107). Despite
this single gene specification and identity of amino acid composition, a number of studies
have provided evidence for the existence of multiple forms of catalase activity in
mammalian organisms. The first electrophoretic separation was carried out by Holmes
and Masters in 1965, and since then multiplicity has been reported by several other
groups (108-110). The major causation of multiplicity in mammalian tissues may be
related to the various possibilities of epigenetic modification, including oxidation of
sulphydryl groups (97,111,112), proteolytic modification (113,114), and modification of
carbohydrate moieties (115,116). Catalase heterogeneity provides a sensitive indication
of the functional variations which occur within separate compartments of subcellular
structure.
The Primary Function of Catalase
Catalase is generally regarded as the single component most closely synonymous
with the peroxisome (98). Catalase is one of the most important intracellular enzymes in
the detoxification of the oxidant hydrogen peroxide (117). Hydrogen peroxide is not only
a normal by-product of cell respiration, being derived from the dismutation of superoxide
by superoxide dismutase, but also arises from the oxidation of fatty acids and the
metabolism of certain compounds (99). Although the enzymatic reaction of catalase has
been intensively studied the exact mechanism of catalysis has not been established and its
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physiological role has remained perplexing (118-121). Catalase has a very high turnover
number, decomposing the H20 2 into 0 2 and H20 at an exceedingly high rate (catalytic
activity). This activity is not its only function. In the presence of very low
concentrations of H20 2 (<10'6M), it will also oxidize electron donors such as ethanol or
phenols (peroxidatic activity). Because catalase has two enzymatic functions and the fact
that H20 2 production in different tissue can vary within a wide range, the actual function
of catalase may vary from tissue to tissue or from one subcellular compartment to
another. Catalase may react either catalytically or peroxidatically depending on the
microenvironment of the cell. Also, the level of H20 2 is regulated physiologically at
concentrations of 10'7 - 10'9M. At these H20 2 concentrations, another enzyme,
glutathione peroxidase, is believed to decompose the H20 2 because it has a higher affinity
for H20 2 than does catalase (119). It is currently believed that both catalase and
glutathione peroxidase contribute to the breakdown of H20 2 in vivo and that both
enzymes have important functions, their relative contribution being dictated by their
subcellular distribution, their localized concentration, and the availability of H20 2,
hydrogen donors, and reduced glutathione (123,124). Glutathione peroxidase is believed
to be of major importance in the breakdown of H20 2. However, the relative contribution
of catalase should increase with increasing concentration of H20 2 (124).
Hydrogen peroxide is a normal cellular metabolite as well as a potentially reactive
form of oxygen which could cause oxidative damage to tissue. It readily permeates
biological membranes and is believed to diffuse from one cell compartment to another,
into interstitial fluid, and into the circulation. The intertissue and intracellular

18

partitioning of catalase and glutathione peroxidase would appear to provide a dual and
complimentary defense mechanism against this mobile source of oxidative stress.
Tissue Distribution and Subcellular Localization
Catalase is ubiquitously present in aerobic cells containing a cytochrome system.
It is missing in most anaerobic organisms, but occurs in the radioresistant species,
micrococcus radioresistants. These observations have cause speculation about its in vivo
role (119,121,125). Catalase is most abundant in the liver and kidney, correlating with
the cellular content of peroxisomes as identified by histochemical techniques (96,98,126).
However, in some species, considerable catalase activities have also been found in the
soluble cytosol of liver (96). A high level of enzyme activity of catalase is also found in
erythrocytes, while lung and pancreas show intermediate values. Very low activities are
found in the heart and brain (127).
Catalase is mainly localized in peroxisomes, but it has also been identified in the
endoplasmic reticulum and cytoplasm (118,119,121). Although it was previously
believed that catalase was present in mitochondria, this view has been questioned (123).
Cytoplasmic catalase is associated with the cellular membrane and may well be involved
in the protection of this structure from lipid peroxidation (128,129). In heart and smooth
muscle, the small amount of catalase is confined to microperoxisomes, situated between
adjacent myofibrils, and often closely related to mitochondria (130-133). In skeletal
muscle, catalase seems to be associated with the sarcoplasmic reticulum (134). The
highest catalase activity has been found in slow oxidative muscle. In a given muscle
type, the catalase activity varies from one region to another (134,135). Catalase in the
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mature red blood cell has been regarded as cytoplasmic. However, several reports have
provided evidence that catalase is associated with or present in the erythrocyte membrane
(136-139). In liver cells, catalase is synthesized as a monomer in the endoplasmic
reticulum and is rapidly transferred to the peroxisomes where final assembly to the
tetramer takes place (140).
It seems to be impossible that a protein of the size of catalase (240,000 daltons)
should be able to pass through the peroxisomal membrane. However, a number of studies
have indicated that catalase is able to pass through the peroxisomal membrane into the
cytoplasm under the appropriate physiological conditions (141).
Catalase and Disease
Xeroderma pigmentation (XP) is an autosomal recessive disease characterized by
extreme sensitivity to sunlight and a high incidence of skin cancer. A decline in catalase
activity has been found to coincide with the first symptom of the catalase and progression
to tumor formation (142). The fibroblasts from patients with XP were found to have only
25% of the expected catalase activity (143). These data suggested that the decrease in
catalase activity permitted an increase in intracellular hydrogen peroxide which was
postulated to be a factor in the eventual development of the malignant process.
The activity of the various intracellular antioxidants was measured in patients
with either acute or chronic renal failure (144). The results suggested that renal failure
induced some form of stress which produced lipid peroxidation and enhanced catalase
activity.
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Ischemia-reperfusion injury occurs when an organ or tissue which has been
deprived of oxygen is reoxygenated. The injury has been associated with oxyradicals
(145). In the isolated heart model, catalase added to the reperfusion solution effectively
provided protection against ischemia-reperfusion injury (146). In another in vitro system
using cultured pulmonary endothelial cells, the addition of catalase reduced the injury
resulting from anoxia-reoxygenation (147).
In a variety of animal species, malignant tumors appear to have reduced catalase
activity. A three-fold decrease in red blood cell catalase activity has been observed in
mice with Ehrlich ascites tumors (148-151). Catalase in the liver was reduced by a tumor
and restored when the tumor was removed (152). A possible mechanism is the
observation that the cachexia and starvation accompanying cancer can cause a significant
depression of catalase activity in many species. This and a number of other possible
explanations have been reviewed by Kampschmidt (153).
Catalase and Cardiac Oxidative Damage
Oxidants are ubiquitous in our aerobic environment and are formed in situ in
tissue and cells by normal metabolism and the metabolism of certain xenobiotics. The
rate of production of reactive oxygen species can be amplified by neutrophil activation,
hyperoxia, metabolism of redox active drugs, radiation exposure, and ischemia
(154,155). Reactive oxygen species, including superoxide, hydrogen peroxide, and
hydroxyl radicals, have been implicated as causative agents in damage to DNA, proteins,
and cell membranes (156-158 ) and involved in the development of various pathological
states such as Adriamycin cardiotoxicity and ischemia-reperfusion injury (159).
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Tissues normally possess biological defense systems to protect against oxidative
damage. Two basic free radical defense systems, primary and secondary, have been
defined (160). The primary defense system consists of antioxidant enzymes, including
superoxide dismutase, catalase, and glutathione peroxidase, and nonenzymatic
components, including glutathione, metallothionein, a-tocopherol, and ascorbate. This
system provides the first line of defense against free radicals. The secondary defense
system includes enzymes and other mechanisms for repairing free radical-induced cell
damage. These systems exist in almost all cell types (117). However, cellular responses
to oxidative stress are different from one cell type to another, suggesting that alterations
in antioxidant defense, such as differential distribution of the antioxidant enzymes, occur
between cell types. Under normal conditions, a balance between free radical generation
and free radical defense system exists (summary in Fig. 3). But, oxygen free radicals can
initiate cellular damage if they overwhelm the antioxidant defense mechanisms.
Cardiac tissue appears to be particularly sensitive to free radical-induced toxicities
(161,162). This is probably not only the result of the relative abundance of mitochondria
and efficient hydroxyl radical formation, but also of a relatively poor antioxidant defense
system (163, 164). Heart, compared to the liver, has a much weaker enzymatic defense
system (165 ). It has been shown that catalase activity in the heart is about 2% of that in
the liver of the mouse (161,163). Catalase, the major enzyme involved in detoxification
of H20 2 in mammalian cells, is thought to be deficient in the heart due to it’s inability to
dispose of reactive oxygen species. This may be responsible for the unusual sensitivity of
the heart to oxidative damage.
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Fig. 3. Free radical generation and free radical defense systems. Free radicals are formed
in tissue and cells by normal metabolism and the metabolism of certain xenobiotics. The
generated superoxide is converted to hydrogen peroxide by superoxide dismutase (SOD).
Hydrogen peroxide is further converted into water and oxygen by glutathione peroxidase
(GSHpx) and catalase. In the normal condition, there is a balance between free radical
generation and free radical defense system.
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The Role of Catalase in Cardioprotection against Oxidative Damage
Several studies have been undertaken to determine the role of catalase in
cardioprotection against oxidative damage. Isolated animal hearts were often used for
such studies. It has been shown that addition of perfusion medium with catalase
significantly reduces ischemia-reperfusion injury to the isolated rat heart by detoxifying
H20 2 (165). The role of catalase in metabolism of H20 2 in the heart tissue was tested
directly by adding H20 2 into perfusion medium (166). In that study, changes in GSSG
concentration in the effluent perfusate were measured as an indicator in GSHpx
metabolism of H20 2. Rats were treated with aminotriazole, an inhibitor of catalase,
before the heart was isolated. This treatment inhibited cardiac catalase activity by 83%.
It was found that in the catalase-depressed heart 50 pM H20 2 caused GSSG efflux at the
rate of 5 nmol/min per g heart, whereas 200 pM H20 2 was required to obtain a similar
rate of GSSG release from the control heart. The result thus shows that catalase, although
present at low levels of activity in the heart compared to other organs, functions in
detoxification of H20 2 in the myocardium.
The cloning and nucleotide sequences of cDNAs for catalase have been reported
for human and rodent tissues (167,168). Many studies were thus conducted using these
cDNAs to increase cellular catalase activity to determine the physiological role of this
enzyme. Transfection of acatalasemic murine fibroblasts with a eukaryotic expression
vector harboring a human catalase cDNA clone produced stably transfected cell lines.
These cells overexpressed catalase activity and exhibited a significant resistance to
oxidative stress relative to the untransfected cells (169). Similar studies have been done
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using other cells. For example, transfection of human bronchial epithelial cells with a
human catalase cDNA elevated their catalase activity and increased the survivability of
the cells when exposed to hyperoxia (170). Human umbilical vein endothelial cells
transfected with a human catalase cDNA also exhibited elevated catalase activity, closely
correlated with increased catalase protein levels (171). When the endothelial cells were
exposed to 500 pM H20 2, all the transfected cells survived, compared to only 37% of
untransfected cells (171). A recent study has shown that simultaneous overexpression of
superoxide dismutase (SOD) and catalase in Drosophila melanogaster extended their life
span by as much as one-third (172). Furthermore, infection with HIV reduced levels of
catalase activity in T cells and enhanced their susceptibility to killing by H20 2.
However, contradictory results were also reported. Transfection of L cells with a
human catalase cDNA elevated catalase activity by 100-fold. These catalase-enriched
cells, however, were more sensitive rather than resistant to the cytoxicity of paraquat,
bleomycin, and Adriamycin than the untransfected cells from which they were derived
(173). The increased sensitivity of the transfected cells to these agents which reduce
dioxygen was in part attributed to the catalase-generated 0 2. It has been interpreted that
by capturing H20 2 and converting it to 0 2, catalase can maintain the concentration of 0 2
either for repeated rounds of chemical reduction or for direct interaction with the drugs.
Several other studies have raised an issue regarding the balance between SOD and
catalase. Transfection of mouse epidermal JB6 cells with a human SOD cDNA increased
the enzyme activity and rendered the cells hypersensitive to the cytotoxicity of
superoxide plus H20 2(174). Although elevation of catalase alone by transfection with
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human catalase cDNA protected the cells from oxidant damage, simultaneous elevation
of the two enzyme activities by transfection provided much greater protection (175). In
the Drosophila study, it was also found that overexpression of SOD alone or catalase
alone had only a minor incremental effect on the average life-span (176,177). These
studies demonstrate the importance of an optimum balance between SOD and catalase.
Statement of Problems
As stated above, the relative deficit in cardiac catalase activity may be an
important factor responsible for the unusual sensitivity of the heart to oxidative damage.
This hypothesis has been continually tested using isolated hearts and other in vitro
models. A major limitation of currently existing approaches is that the isolated heart
perfused with catalase serves as a model for studying only acute toxicity. In cancer
chemotherapy, chronic rather than acute drug toxicity is a major problem. Thus, a stable,
chronic rather than short-term approach is more appropriate for these studies. In addition,
transfection of cultured cells with catalase cDNA provides only in vitro understanding of
the role of catalase in detoxification of reactive free radicals. Contradictory conclusions
may result from this limitation. For example, in culture, the 0 2 generated from H20 2 by
catalase may be responsible for the increased sensitivity of the catalase-enriched L cells
to oxidant toxicity (174). This may not be the same case in vivo because of the more
complicated regulation of 0 2 sense and transport systems. Therefore an unique in vivo
model is clearly required to overcome these limitations and to precisely determine the
role of catalase in protection against Adriamycin cardiotoxicity.
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Significance of the research
Heart damage is a severe toxic effect of Adriamycin, resulting in the limitation of
its application in cancer chemotherapy. Therefore an understanding of the mechanism for
the unusual sensitivity of the heart to Adriamycin toxicity is necessary for the
development of experimental and clinical approaches to improved use of Adriamycin in
cancer chemotherapy. A possible mechanism for Adriamycin cardiotoxicity is the
production of oxygen free radicals during its intracellular metabolism. The heart with a
weak antioxidant system, in particular low catalase activity, may be responsible for the
unusual susceptibility of the heart to Adriamycin toxicity. Therefore, we decided to
develop a transgenic mouse model in which catalase is constitutively overexpressed
specifically in the heart tissue. This unique model would thus provide an unequivocal
approach to understanding the role of catalase in cardiac protection against Adriamycin
toxicity as well as other cardiac injury, such as ischemia-reperfusion damage and many
other oxidative deteriorations.

CHAPTER II

MATERIALS AND METHODS
Construction of the transgene for overexpressing catalase specifically in the heart
A transgene, designated MyCat, was constructed for over expression of catalase in
cardiac tissue of transgenic mice (summary in Fig. 4). The procedures for plasmid
construction and DNA preparation were as described by Maniatis (178). All plasmids
were grown in the DH5a ™competent cells. The plasmid Clone 20 (179), pRCA38 (180)
and pRip-InsII (181) were used. The plasmid pRCA38 (provided by Dr. Shuichi Furuta,
Shishu University School of Medicine, Japan), containing the complete coding region of
rat catalase cDNA, was digested with Nco I followed by treatment with the Klenow
fragment of DNA polymerase to fill the single-stranded end. It was then digested with
Hind III and extracted with phenol/chloroform. The plasmid Clone 20 ( provided by Dr.
Jeffrey Robbins, University of Cincinnati College of Medicine), containing the alpha
cardiac myosin heavy chain (MHC) promoter, was digested by Sal I, filled in with
Klenow and digested with Hind III. The plasmid DNAs were then ligated to produce the
MyCat I plasmid where the rat catalase cDNA is under the regulation of the MHC
promoter. A 600-bp Xhol blunt-Hind III genomic fragment of the plasmid pRip-Ins II
(provided by Dr. Paul Epstein, University of North Dakota School of Medicine) was

28

29

Fig. 4. Construction of MyCat transgene, the plasmids Clone 20 and pRCA 38 were
digested with sal I and Nco I respectively. The gaps were filled with klenow and both
plasmids digested with Hind III and ligated to produce the MyCat I plasmid. A 600-bp
fragment of Xho I and Hind III digested Rip-Int II gene and BamH I / Hind III fragement
of MyCat I were ligated to yield MyCat II. Then MyCat II plasmid was digested by Sma
I and Hind III and ligated together to generate MyCat III plasmid.

30

'•*“

■**

'rsruttcnc

31

inserted behind the catalase cDNA in BamHI blunt-Hind III sites of the MyCat I plasmid
to provide polyadenylation site and termination signals, producing the MyCat II plasmid.
For modification of MyCat II, a 1400-bp fragment containing two introns and one exon
of the Insulin gene were moved from the MyCat II by Sma I/Hind III digestion, then
ligated together to yield MyCat III plasmid. For production of transgenic mice, plasmid
sequences were removed from the MyCat III by Notl digestion and an 8-kb MyCat
transgene (shown in Fig.5) was generated.
Production of transgenic mice
Transgenic mice were generated by microinjection of the transgene into single
cell embryos by standard techniques (182 ). Prior to injection, the transgene was purified
by Nal-glass bead extraction (geneclean, BIO 101) and filtered through 0.22 pm filters.
The DNA sample for microinjection was free of contaminants that might harm the eggs,
such as traces of phenol, ethanol, or enzymes. In addition, it was essential to get rid of
any particulate matter that might clog the injection needles. Embryos were isolated from
superovulation 4- to 6 week old FVB females that were treated by pregnant mare's serum
(PMS) and human chorionic gonadotropin (hCG). On average, 20-30 eggs were
recovered from the superovulated female. Microinjections of purified DNA at 2 pg/ml
in 10 mM Tris-HCl / 0.1 mM EDTA, pH 7.6, were inserted into one pronucleus for each
embryo, 12-14h after fertilization. Embryos that survived microinjection were implanted
into pseudopregnant females and allowed to develop to term. Founder mice were crossed
with FVB mates and transgenic lines were maintained in the FVB strains. A summary of
the procedure is given in Fig.6.

32

Fig. 5. Structure of the 8-kb MyCat transgene insert. The hatched and open boxes
indicate the promoter and first three noncoding exons of the alpha cardiac MHC
gene, respectively. The black box indicates the catalase cDNA and the slashed box
indicates 3' genomic sequences of the rat insulin II gene. Arrow 1 shows the
transcription initiation site, arrows 2 and 3 show the catalase start and stop codon,
respectively. Arrow 4 shows the polyadenylation sequence from the rat insulin II
gene.
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Fig. 6. Embryos were isolated from superovulation 4- to 6 week old FVB females that
were treated by PMS and hCG. On average, 20-30 eggs were recovered from the
superovulated female. The purified DNA at 2 |ig/ml in 10 mM Tris-HCl / 0.1 mM
EDTA, pH 7.6, was microinjected into one pronucleus for each embryo, 12-14h after
fertilization. Embryos that survived microinjection were implanted into pseudopregnant
females and allowed to develop to term. Transgenic founders were identified by
Southern blot, Dot blot and PCR analysis.
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Molecular Analyses
Southern blot
Genomic DNA was isolated from tails clipped from 20- to 30- day - old mice
under anesthesia by using a QiaAmp kit (Qiagen Inc. Chatsworth, CA). Five pg of tail
DNA was digested with EcoRI and then extracted with phenol/CHCl3. The DNA was
separated by agarose gel electrophoresis and was then depurinated in 0.25 N HC1. After
denatured in 0.4 N NaOH, DNA was transferred to a nylon membrane in an alkaline
solution of 0.4 N NaOH. The membrane was incubated with church buffer consisting of
0.5 M Na2HP04, 1% BSA, and 0.7% SDS, pH 7.0 and 0.1 mg/ml of heat-denatured tRNA
and salmon sperm DNA at 65°C for a period of 3 hr and then hybridized with a 32Plabeled probe in church buffer. After hybridization, the membrane was washed twice
with wash buffer A (1% BSA, 5% SDS, 0.04 M PB, 1 mM EDTA) and four times with
wash buffer B (1% BSA, 0.04 M PB, and 1 mM EDTA) and exposed to X-ray film at 80°C. The probe used was a 550-bp Smal and Notl fragment of the MyCat transgene. If
the chimeric transgene was present in the genome, EcoRI digestion would result in a
fragment that would specifically hybridize with the probe.
Ppt blpt

One pg genomic DNA was digested with restriction endonuclease EcoRI and was
denatured in 200 pi of 0.25 N NaOH, and 0.5 N NaCl for 10 min. The reaction mixture
was then loaded in wells of the Bio-Rad apparatus. After 30 min, the sample was sucked
through the membrane. The membrane was then washed in 0.5 M NaCl, 0.5M Tris pH
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7.5 for 1 min and baked at 80 °C for 30 min. The hybridization procedure was the same
as the Southern blot.
Polymerase chain reaction ('PCRO
The PCR method was used to identify transgenic mice. The oligonucleotide
primers of 20-mer for the PCR analysis was obtained from DNA International. The 5'
primer derives from the MHC promoter sequence and the 3' covers the catalase codon.
The primer sequences are: 5' “AGG CTA CGG TGT AAA AGA GG ” and 3' “ GTG
GGT GAC CTC AAA GTA TC ”. This design ensures the 450-bp PCR product will not
obtain from the normal mouse DNA. The PCR conditions are as follows: to a sterile
0.5-ml tube was added 10 y 1of 5X F buffer (10 mM potassium chloride, 300 mM Tris
hydrochloride, pH 9.0 and 75 mM ammonium sulfate ), 5 y\ of a 10 mM aqueous
deoxynucleotide triphosphate solution, 0.2 yl Taq polymerase, 0.5 y\ each of the 5' and
the 3' primers (2.5 yg/yi), 1 yl NAT oligo (2.5 yg/yl), 5 yl of the DNA solution from the
mouse tail digestion, and water to make a total volume of 50 yl. The PTC-100
Programmable Thermal Controller with the Hot Bonnet/60 was purchased from MJ
Research, Inc. The PCR cycles are 1 min at 94°C, 2 min at 55°C, and 3 min at 72°C.
After completion of 34 PCR cycles, the mixture was incubated for 7 min at 72°C. The
PCR products were stored at -20°C. To analyze the PCR products, 25 yl of the mixture
was subjected to 1% agarose gel electrophoresis.
Northern blot analysis
Total RNA was extracted from the myocardium tissue using the RNAzol B
method (Cinna/Biotex). RNA was quantified spectrophotometrically and confirmed by
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ethidium bromide staining of 18S and 28S ribosomal RNA. RNA was then denatured in
formaldehyde, fractionated on 1.1% agarose gels and transferred to nylon membranes.
The probe corresponding to a 900-bp Hind III and Bgl II fragment of the rat catalase
cDNA was randomly labeled with [a-32P]dCTP (DuPont/NEN Research Products,
Boston, MA) using the Klenow fragment of DNA polymerase I (Bethesda Research
Laboratories, Gaithersburg, MD) and purified by chromatography (Sephadex G-50,
Sigma) before hybridization. Hybridization and wash procedures were conducted using
previously published methods. After autoradiography, the membrane was stripped and
rehybridized with human beta-actin cDNA probe to ensure the integrity of the RNA
sample and to confirm that equal amounts of RNA had been loaded onto all lanes.
Autoradiographic images were scanned and analyzed using the MCID system from
Imaging Research Inc. (Ontario, Canada), which is available within our department.
Biochemical analyses
Catalase
The method for determination of catalase activity described by Aebi [183] was
followed with some modification. Catalase exerts decompose H20 2 to give H20 and 0 2.
The decomposition of H20 2 can be followed directly by the decrease in absorbance at 240
nm. Therefore, the difference in absorbance ( A240) per unit time is a measure of the
catalase activity. To avoid inactivation of the enzyme during the assay or formation of
bubbles in the cuvette due to the liberation of 0 2, it is necessary to use a relatively low
H20 2 concentration (10 mM, final reaction concentration). Tissue samples were placed in
liquid nitrogen and then at -80° C for less than 36 hr. Myocardial tissue was
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homogenized in 10 volumes of 1.0% triton X-100 using a variable speed tissue tearer
(Biospe, Products, Inc.). The homogenate was then centrifuged at 10,000 rpm at 4° C for
20 min to remove nuclei and cell debris. The supernatant was diluted with the assay
buffer, 50 mM KH2PO4/50 mM Na2HP04 (1:1.5, pH 7.0), to avoid the UV absorption of
Triton X-100. Catalase activity was measured by spectrophotometeric analysis at 240
nm. Two ml of the sample was apaced in a cuvette. The reaction was initiated by
adding 1 ml 30 mM H20 2, and the decrease in absorbance at 240 nm was monitored at
25° C for 1.0 min. A portion of the remaining sample was used for protein
determination. Specific activity was expressed as pmol H20 2/min per milligram of
protein.
Superoxide dismutase (SODl
Myocardial tissue was washed with saline to remove excess connective tissu and
red blood cells. The tissue was then minced in 3 vol of 0.05 M phosphate buffer, pH 7.8,
using scissors. The minced tissue was homogenized with a Tekmar SDT ultraspeed
tissue grinder (6 x 5-s bursts). The homogenized samples were centrifuged at 20,000g for
60 min and the supernatant was assayed. All procedures were performed on ice. The
method used for the assay of SOD activity is a modification of an indirect inhibition
assay developed by Beauchamp and Fridovich [184]. Xanthine-xanthine oxidase was
utilized to generate a superoxide flux. Nitroblue tetrazolium (NBT) reduction by 0 2' to
blue formazan was followed at 560 nm with a Beckman model DU-65 spectrophotometer
at room temperature. The rate of NBT reduction in the absence of tissue was used as the
reference rate. When increasing amounts of the homogenized supernatant (containing
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SOD activity) were added to the system, the rate of NBT reduction was progressively
inhibited. The amount of inhibition is defined as a percentage of the reference rate of
NBT reduction when SOD activity is not present. The data were plotted as percentage
inhibition vs protein concentration. One unit of activity is defined as the amount of
protein necessary to decrease the reference rate to 50% of maximum inhibition. The
assay mixture also contains catalase to remove H20 2 and DETAPAC to chelate metal ions
capable of redox cycling and interfering with the assay system. NaCN (5 mM) was added
(for 45-50 min) to assay MnSOD activity, if required. The MnSOD activity was
subtracted from the total SOD activity to calculate the CuZnSOD activity. Each 1-ml
assay tube contained final concentrations of the following reagents: 50 mM potassium
phosphate buffer, pH 7.8; 1 mM DETAPAC; 1 unit catalase; 5.6 x 10'5M NBT; 0.1 mM
xanthine; enough xanthine oxidase to achieve the required reference rate; and sample
ranging from 0 to 500 \ . g of tissue protein. Protein content was measured using the
j

Pierce BCA protein assay reagents as previously described [185].
Glutathione peroxidase IGSHpxl
This enzyme activity was measured using the method described by Flohe and
Gunzler [186]. The homogenized tissue sample in 0.1 M potassium phosphate buffer
containing 1.0 mM EDTA, pH 7.0, was centrifuged at 20,000g for 60 min. The
supernatant fraction was used for the assay of GSHpx. The assay is based on GSSG
formation during the GSHpx reaction. GSSG is instantly formed and continuously
reduced by an excess of glutathione reductase (GR), providing for a constant level of
GSH. NADPH is the co-factor required by GR. Therefore, the GSHpx activity is
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measured by photometrically monitoring the concomitant oxidation of NADPH. The
reaction mixture contains 0.5 ml phosphate buffer (pH 7.0), 0.1 ml sample, 0.1 ml GR
(0.24 U), and 0.1 ml of 10 mM GSH. The mixture was preincubated for 10 min at 37°C.
Following incubation, 0.1 ml 1.5 mM NADPH in 0.1% NaHC03 was added to the
mixture, and the hydroperoxide-independent consumption of NADPH was monitored for
3 min. The overall reaction was started by adding 0.1 mM of prewarmed hydrogen
peroxide (1.5 mM). The decrease in absorbance at 340 nm was monitored with a
Beckman DU-65 spectrophotometer. The nonenzymatic reaction rate was
correspondingly assessed by replacing the sample with buffer. One unit of the enzyme is
defined as the amount of enzyme that catalyzes the oxidation of one pmole of NADPH
per min monitored at 340 nm.
Glutathione Reductase IGRl
This enzyme activity was measured using the method described by Carlberg and
Mannervik [187]. The homogenized tissue sample in 0.2 M potassium phosphate buffer
containing 2.0 mM EDTA, pH 7.0, was centrifuged at 10,000 rpm for 60 min. The
supernatant was used for the assay of GR. The assay is based on reduction of glutathione
disulfide (GSSG) to glutathione by glutathione reductase. NADPH is the co-factor
required by GR. Therefore, the GR activity was measured by photometrically monitoring
the concomitant oxidation of NADPH. To a 1-ml cuvette, 0.5 ml of 0.2 M phosphate
buffer (pH 7.0), 0.1 ml of 2 mM NADPH in 10 mM tris-HCl (pH 7.0), 0.1 ml of 20 mM
GSSG, and 0.2 ml deionized water were added. The reaction was initiated by the
addition of enzyme to the cuvette and the decrease in absorbance at 340 nm was followed
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at 30 °C. A unit of glutathione reductase activity is defined as the amount of enzyme that
catalyzes the reduction of 1 )imol of NADPH per minute. Specific activity is expressed
in units per milligram of protein.
Glutathione (GSH and GSSG)
The DTNB-glutathione reductase recycling assay first reported by Owens and
Belcher (188) and later modified by Tietze (189) was used to measure glutathione. The
recycling assay for total GSH (GSH + GSSG, in GSH equivalents) is a sensitive and
specific enzymatic procedure. In this reaction, GSH is oxidized by 5,5'-dithiobis (2nitrobenzoic acid) (DTNB) to give GSSG with stoichiometric formation of 5-thio-2nitrobenzoic acid (TNB). GSSG is reduced to GSH by the action of the highly specific
glutathione reductase (GSSG reductase) and NADPH. The rate of TNB formation is
followed at 412 nm and is proportional to the sum of GSH and GSSG present. Tissues
were homogenized in 10 volumes of 5% (w/v) 5-sulfosalicylic acid at 4 °C. The
homogenate was centrifuged at 10,000 g for 15 min and the supernatant was assayed for
GSH by the DTNB-glutathione reductase recycling assay. The 1.0 ml reaction mixture
contained 190 //I stock buffer (143 mM sodium phosphate and 6.3 mM Na4-EDTA, pH
7.5), 700 (A 0.248 mg NADPH/ml in stock buffer, 100 ^1 6 mM DTNB and 10 (A sample.
The assay was initiated by addition of 10

of 266 U glutathione reductase/ml.

Standards were assayed in parallel under the same conditions as tissue samples.
Metallothionein 1MT)
Total tissue MT concentrations were determined by the cadmium-hemoglobin
affinity assay (140). The high affinity of MT for mercury and cadmium, coupled with

43

good stability at low pH and high temperatures, has served as the basis for the
development of several simple, rapid, and inexpensive metal-binding assays to quantitate
MT in biological samples. The assay used depended on the ability of heat-precipitable
protein (crude bovine hemoglobin) to bind and remove excess cadmium that was not
bound to MT. Tissues were removed, rinsed in ice-cold buffer, and then homogenized in
4 vol of 10 mM Tris-HCl buffer (pH 7.0), with a glass homogenizer and a teflon pestle.
The homogenate was centrifuged at 10,000g for 10 min, and the supernatant fraction was
heated for 2 min in a boiling water bath. The heated samples were then centrifuged at
10,000g for 2 min to remove precipitated proteins. Heat-denatured supernatant fractions
were used to measure MT levels. Two hundred microliters of isotope labeled 109Cd
solution (2 |ig/ml, 1 pCi/ml) was mixed with 200 pi of sample (heat denatured
supernatant) and allowed to incubate at room temperature for 10 min. Then 100 pi of a
2% bovine hemoglobin solution was added to the tubes, mixed and heated for 2 min.
After 2 min in the boiling water bath, the tubes were placed on ice for several minutes,
centrifuged at 10,000g for 2 min in a microfuge, and another 100 ul aliquot of 2%
hemoglobin was added. The heating, cooling, and centrifugation were then repeated. A
500 pi aliquot of the supernatant fraction was carefully removed from the microfuge tube
and transferred to a clean y -counting tube. The amount of radioactivity in the supernatant
fraction was then determined by direct y counting. Blank samples were used by replacing
the tissue sample with the buffer. Also, samples to determine the total radioactivity (200
pi of buffer added in place of hemoglobin) were run with the assay. The amount of MT
was calculated and expressed as units of micrograms MT per gram of tissue.
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Determination of Adriamycin cardiotoxicity
Treatment of experimental animals
Adriamycin solution was prepared from Adriamycin hydrochloride (sigma)
dissolved in 0.9% saline. For the study of acute toxicity, transgenic mice and normal
controls (7 weeks old, without regard to sex, because our preliminary studies showed no
difference in cardiac toxic responses to doxorubicin between males and females) were
injected introperitoneally (ip) with Adriamycin hydrochloride (Sigma) at 20 mg/kg. Four
days after receiving the Adriamycin injection, the experimental animals were anesthetized
ip injection with sodium pentobarbital (65 mg/kg body weight, Vet Labs, Lenexa, KS)
and cardiotoxicity was determined as described below.
For the chronic study, the dorsal or ventral tail veins of the transgenic and
nontransgenic control mice were chosen as the site of intravenous injection (iv) of
Adriamycin. A device to restrain mice for the tail vein injection has been described by
Boggs [191]. To make the injection easier, the tail was warmed for 5-10 sec in ajar of
warm water to dilate the tail vein. The tail veins in the FVB (albino) mice are visualized
as thin red-blue lines coursing along the top (dorsal tail vein) and bottom (ventral tail
vein). A 26-gauge 1/2-inch needle was used for the injection. Adriamycin saline
solutions were injected at 5ml/kg of body weight at doses of 9 mg/kg every other week,
for a total of five injections over 10 weeks (cumulative doses of 45 mg/kg). All animals
were killed on the second day after the last injection. Adriamycin induced cardiac
morphological changes were determined by light and electron microscopy.
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Examination of Adriamycin-induced morphological changes
Both light- and electron-microscopic techniques were employed to examine
Adriamycin-induced morphological changes as previously described [192]. We have
found that perfusion of the heart in situ is a much better way to preserve the tissue
integrity and prevent artifacts. Therefore, the in situ perfusion procedure was used,
described as follows: into the cardiac apex of the anesthetized mice a cannulated needle
was inserted about 3 mm, slightly pulled back, with 20 ml syringe filled with wash-out
solution (6.6 g paraformaldehyde dissolved in 500 ml distilled water; 1.6 ml 50%
glutaraldehyde; 360 ml 0.2 N sodium cacodylate buffer, pH 7.2-7.4; 0.5 g CaCl3; 0.25
g A1C13; 1.0 g procaine hydrochloride; add water to make final volume of 1000 ml).
If fresh blood (light red color) comes out smoothly, the needle is in the proper position
of the left ventricle (needle 25 G 3/8, tubing: silastic medical grade, 0.02" ID and
0.037" OD, CMS#508-002). The right atrium was cut with micro surgical scissors to
allow blood and solutions to wash out. The heart was perfused with the wash-out
solution (room temperature) at a flow rate of 5 ml/min for 2-3 min until flowing from
right atrium became clear. This was followed by perfusion with Karnovsky's fixative
(10 g paraformaldehyde dissolved in 500 ml distilled water; 50.0 ml 25%
glutaraldehyde; 360 ml of 0.2 N sodium cacodylate buffer, pH 7.2-7.4; 0.5 g CaCl2;
0.25 g A1C13; add water to make final volume of 1000 ml) at a rate of 3 ml/min for 10
min with 20-ml syringe at 4°C. The perfusion quality was indicated by mouse lip, tail
and eyes becoming pale, liver becoming light gray and hard, and the whole body
becoming hard. The heart was removed and immersed in pre-cooled (4°C)
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Karnovsky's fixative immediately. Into each tissue vial, two ml of pre-cooled
Karnovsky's fixative was added (about 10 volumes of tissue blocks). A piece of dental
wax was put into a petri dish, and adequate fixative was added onto the tissue. The left
ventricle (LV) and interventricular septum (IVS) were dissected and cut into 1 mm3
with a razor blade. Six pieces of each LV and IVS were put into each vial filled with
pre-cooled Karnovsky’s fixative at 4 °C for 90 min, then rinsed 3 times with 0.2 N
sodium cacodylate buffer, pH 7.4, and post-fixed with 1% ostium tetroxide at 4 °C in
the dark for 90 min (osmium solution was mixed in the following way: 1 part of 2 %
osmium tetroxide to 1 part of S-collidine buffer, pH 7.4). The blocks were rinsed 3x
with distilled H20 and dehydrated with ethanol and propylene oxide according to the
following schedule: ethanol 50% 5 min; 70% 5 min; 80% 5 min; 95% 10 min; 95% 10
min; 100% 20 min; 100% 30 min; propylene oxide 20 min for 3 times under hood.
Then the blocks were infiltrated with propylene oxide/Epon Araldite (2:1) for 1 hour
(with the cap loose), propylene oxide/Epon Araldite (1:2) for 1 hour, followed by
Epon Araldite for 1 hour or longer. (Epon Araldite protocol: 10 ml of Araldite 506
resin, 10 ml of tEpon™-812 Epoxy resin, 24 ml of Dodecenyl Succinic Anhydride and
0.66 ml of 2,4,6-tri-dimethylamino methyl phenol). Then three blocks were labeled
and embedded in flat embedding molds with freshly prepared Epon/Araldite and cured
on the uncovered mold in 55° C oven for 48 hours. Longitudinally and cross
sectionally oriented myocardial fibers were selected under light microscope (Olympus
BH-2) on semi-thin sections stained with 1% toluidine blue. Subsequently, ultrathin
sections obtained with a diamond knife were stained with 2% uranyl acetate and 0.18%
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lead citrate and examined with JEM-100 S transmission electron microscope (JEOL,
USA, INC) operated at 80 kV.
Myocardial lesions were evaluated on a median section of the whole heart and
scored as described in the Table 1 according to their severity and extension (192). The
product of the severity for the extension score gave the total cardiotoxicity score (from 0
to 10) of each animal, from which the mean total score (MTS) for each animal group was
calculated. These hearts were scored in a completely blinded fashion. The score was not
corrected for the background histological damage due to preparation and handling of the
hearts.
Functional determination
To isolate atria the experimental procedure described by de Jong et al. [193] was
used with modifications. Both transgenic and control mice of either sex weighing from
20-3Og were sacrificed under anesthesia by sodium pentobarbital and the entire heart
was quickly removed. The heart was placed in Dulbecco's calcium-free phosphate buffer
(pH 7.4) containing NaCl (136.9 mM); KC1 (2.68 mM); KH2P 0 4 (1.47 mM); and
NaH2P 0 4 (8.0 mM) for 15 min. This incubation causes heart arrest. Atria were
separated from ventricles and placed in a 20-ml organ bath containing Krebs-Henseleit
(KH) buffer of the following composition: NaCl (117.5 mM); KC1 (5.6 mM); M gS04
(1.18 mM); CaCl2 (2.5 mM); NaH2P 04 (1.28 mM); NaHC03 (25.0 mM); glucose (11.1
mM); pH 7.4 gassed with 5% C 02 in 95% 0 2 (20 inmHg). This incubation started at
ambient temperature, but was gradually warmed to 37°C. Following a 30-min
stabilization period, a preload tension of 0.25g - 0.5g was applied to each atrial
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preparation. The isolated left atrium was stimulated to contract with square wave pulses
of 3 msec duration and a voltage of 1.5 times the threshold value. The pluses were
generated by a Grass S88 stimulator (Quincy, MA) at a fixed frequency of 4 Hz. The
muscle contractions were recorded isometrically by a Kulite Semiconductor BGG-lOgm
(Leonia, NS) force transducer and a Gould TA2000 recorder (Lveland, OH). The
changes of spontaneously frequency (beats/min) recorded from the right atria were used
to evaluate chronotropic effects.

Table 1. Morphological evaluation of cardiac lesion
Severity degree (a)
1: sarcoplasmic microvacuolization and/or inclusions, interstitial or cellular edema;
2: as in 1 plus sarcoplasmatic macrovacuolizations or atrophia, necrosis, fibrosis,
endocardial lesions and thromby;
Extension degree (b)
0:
.5:
1:
2:
3:
4:
5:

no lesion at all;
less than 10 single altered myocytes on the whole heart section;
scattered single altered myocytes;
scattered small groups of altered myocytes;
spread small groups of altered myocyted;
confluent groups of altered myocytes;
most of the cells damaged:

Total cardiotoxicity = a x b

To determine whether elevated catalase activity in the transgenic mice provides
protection against Adriamycin-induced cardiac functional change, a transgenic mouse
line in which catalase activity is 60-fold higher than normal was selected. After an
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equilibration period of 30 min with 3 intermittent washings, Adriamycin was added to
the incubation KH buffer to a final concentration of 100 pm and the contraction of the
atrium was monitored for 60 min. Time-course effects of Adriamycin on contractile
force and heart rate were determined using isolated left and right atrium, respectively.
Contractile force and frequency at the time of Adriamycin addition was set at
100% .
Lipid peroxidation
Malonaldehyde (MDA) and 4-hydroxyalkenals are important decomposition
products of peroxides derived from polyunsaturated fatty acids and related esters. It has
been recognized that measurement of such aldehydes provides a convenient index of lipid
peroxidation. Because the classical MDA determination by the thiobarbituric-acid
method (TBA) is influenced by several interferences and its reproducibility is not
satisfactory (194), a modified assay was used in the present study (195). This modified
method measures the products of lipid peroxidation, MDA and 4-hydroxyalkenal. A
commercial kit based on this method was used (LPO-586, Bioxytech S.A., France). The
LPO-586 method takes advantage of a chromogenic reagent R1 that reacts with MDA
and 4-hydroxyalkenals at 45 °C. Condensation of one molecule of either MDA or 4hydroxyalkenal with 2 molecules of reagent R1 yields a stable chromophore with
maximal absorbance at the 586-nm wavelength. Hearts were rapidly excised, trimmed of
connecting tissue, and washed free of blood with ice-cold saline. They were then blotted
and weighed. Temperature was maintained at 4 °C throughout the experiment. 1/10
homogenates (g/ml) were obtained in 20 mM Tris-HCl buffer, pH 7.4. The homogenates
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were centrifuged at 2500g for 10 min at 4 °C. The supernatant was used to assay. For
each assay, 650 pi of freshly prepared R1 solution and 200 pi sample was added and
mixed, then 150 pi of methanesulfonic acid R2 was added to start the reaction. The
reaction mixture was incubated for 40 min in a 45 °C water bath and the absorbance at
586 nm was measured by using a Beckman Model DU-65 spectrophotometer. Solutions
S 1 and S2 were used to prepare standards for 4-hydroxynonenal and MDA, respectively.
The level of lipid peroxidation was expressed as nmol of MDA and 4-hydroxynonenal
per gram tissue.
Creatine phosphokinase (CPK') activity
Serum CPK activity was assayed as described by Oliver (196). CPK catalyzes the
reaction between creatine phosphate and adenosine diphosphate (ADP), forming creatine
and adenosine triphosphate (ATP). The ATP formed is utilized to phosphorylate glucose,
producing glucose-6-phosphate (G-6-P) in the presence of hexokinase (HK).
Subsequently, G-6-P is oxidized to 6-phosphogluconate (6-PG) in the presence of
nicotinamide adenine dinucleotide (NAD) by glucose-6-phosphate dehydrogenase (G-6PDH). During this oxidation, an equimolar amount of NAD is reduced to NADH, which
can be monitored at 340 nm. The rate of change in absorbance is directly proportional to
CPK activity. A CPK Test kit (CK-20, Sigma) based on this method was obtained from
Sigma. Blood was collected from the inferior vena cava of the anesthetized animals and
serum was obtained by a serum separator apparatus (Becton Dickinson and Company,
Rutherford, NJ). To a 1.0-ml cuvette, 1.0 ml CPK reagent and 0.03 ml sample was added
and incubated at 30° C for 3 min. The increase of absorbance at 340 nm was recorded at
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30-second intervals for a period of 3 minutes. The CPK activity was calculated by using
the millimolar absorbency of NADH, which is 6.22 at 340 nm and expressed as units of
enzyme activity per liter serum (U/L). One unit of activity was defined as the amount of
enzyme which produces one pmol NADH per minute under the conditions of the assay
procedure.
Statistical analysis
The data obtained was initially analyzed by ANOVA. The differences were further
analyzed by Duncan's multiple-range test or other appropriate methods. Differences
between treatments were considered significant at p<0.05.

CHAPTER III

STUDY I: CONSTITUTIVE OVEREXPRESSION OF CATALASE SPECIFICALLY
IN THE HEART OF TRANSGENIC MICE

Cardiac tissue appears to be particularly sensitive to oxidative damage because the
enzymes that protect against oxidative damage are markedly lower in the heart than in
other tissues in the body (161-164). It has been shown that catalase activity in the heart is
about 2% of that in the liver of the human (160), the mouse (163), and the rat (161). It is
unknown, however, whether the low catalase activity in the heart is responsible for the
high sensitivity of this organ to oxidative damage. Although several studies have been
undertaken to determine the role of catalase in cardioprotection against oxidative injury,
current approaches using isolated heart perfused with catalase have limited application.
Exogenously added catalase may not be able to function intracellularly, but may react
only with H20 2 directly in the perfusion medium. Thus, the relationship between the low
constitutive catalase activity and the high sensitivity to oxidative stress in the heart has
not been defined. A unique in vivo model is required to overcome these limitations and
to precisely determine the role of catalase in protection against oxidative cardiotoxicity.
In this study, a transgenic mouse model in which catalase activity is constitutively
overexpressed specifically in the heart tissue has been produced. This unique model thus
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transgenic control. As shown in Fig. 8, catalase activity was markedly elevated in the
transgenic hearts. This elevation ranges from 2- to 650-fold higher than normal among
the transgenic lines. There was no significant difference in the catalase activity between
males and females within the same transgenic line (data not shown). The elevated
catalase activity in the transgenic mice was roughly correlated with the level of mRNA
for catalase in the transgenic heart as shown in Fig. 7. The results clearly demonstrate
that the increased catalase activity results from expression of the MyCat transgene.
Characterization of transgenic mice
It is important to know whether the catalase activity is elevated to the same
extent in both atria and ventricles. As shown in Fig. 9, the elevated levels of catalase
in atria and ventricles from 5 representative transgenic lines are the same. These 5
lines were also used for the experiments described below.
To determine whether the elevated catalase expression is specific to the heart,
catalase activities in other tissues including liver, lung, and skeletal muscles of the
transgenic mice were measured. As shown in Fig. 10, catalase activities in all these
tissues remained the same as controls. There was no alteration in the enzyme activity in
any of these tissues in the non-transgenic littermates.
We then determined whether other antioxidant enzyme activities in the transgenic
heart were altered. The enzymatic activities of SOD, GSHpx, and GR were measured in
the catalase-enriched transgenic hearts. As shown in Table 2, none of these enzyme
activities were changed. We also measured the concentrations of two important
nonenzymatic antioxidant components, GSH and MT. There is no alteration in either of

56

the two components in the catalase-enriched transgenic hearts (Table 2).
Therefore, characterization of the transgenic mice shows that only catalase, not
other antioxidant components, is overexpressed specifically in both atria and ventricles of
the heart. The elevated levels of catalase activity range from 2- to 630-fold higher than
normal among the 15 transgenic lines. This enzyme activity is not altered in any other
organs including liver, kidneys, lungs, and skeletal muscles of any of the 5 tested
transgenic mouse lines. Other antioxidant systems were not altered in the transgenic
hearts.
Discussion
Heart damage is a severe toxic effect of Adriamycin, resulting in the limitation of
its application in cancer chemotherapy. Therefore, an understanding of the mechanism
for the unusual susceptibility of the heart to Adriamycin toxicity is necessary for the
development of experimental and clinical approaches to improved use of Adriamycin in
cancer chemotherapy. A possible mechanism for Adriamycin cardiotoxicity is the
production of oxygen free radicals during its intracellular metabolism. The heart,
however, has a weak antioxidant system. In particular, the catalase activity is much
lower in the heart than in other organs. It is therefore postulated that low catalase activity
in the heart may be a major factor responsible for the high sensitivity. Although several
studies have been undertaken to determine the role of catalase in cardioprotection against
oxidative injury, the existing approaches have limited application. In this study, we
developed the transgenic mouse model in which catalase activity is constitutively
overexpressed specifically in the heart tissue. This unique model would thus provide an

57

Fig. 7. Representative Northern blot analysis of catalase mRNA in the hearts of the 15
different transgenic mouse lines and the controls. The amount of mRNA detected in each
line cofficiently correlates with the level of catalase activity in the heart. Three bands
hybridized with the catalase probe in transgenic samples. Only the smallest band
corresponds to the expected, fully processed transgenic mRNA. The arrow indicates the
position of the single control band.
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Fig. 8. Catalase activities in the heart from each of the 15 different transgenic mouse
lines in comparison with that of controls (Cont). Each value is the average of 6
determinations (mean + SD)
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Fig. 9. Comparison of elevated catalase activities in the atria and ventricles in 5
representative transgenic mouse lines (n=3). There is no significant difference (p>0.1) in
The catalase activity between the atria and ventricles in any of these transgenic lines.
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Fig. 10. Comparison of catalase activities in the liver, kidney, lung, and skeletal muscles
rom the left rear leg (Ml) and the stomach (M2) of 5 representative transgenic mouse
lines sameshown in Fig. 7. The tissues were obtained from control mice (Cont) and
MyCat transgenic (MyCat+). The data represent mean + SD from 6 control animals and
representative transgenic lines with 3 animals for each line.
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unequivocal approach to understanding the role of catalase in cardiac protection against
Adriamycin toxicity.
Table 2. Enzyme activities of SOD, GSHpx, and GR, and concentrations of GSH and
MT in the hearts of control and MyCat transgenic mice
Control

MyCat

SOD (U/g wet wt)

98.6 ±0.3

108.3 ± 13.4

GSHpx (nmol NADPH/min mg protein)

29.8 ±4.4

26.2 ±3.0

GR (nmol NADPH/min mg protein)

14.2 ± 1.7

16.0 ±1.4

GSH (pg/g wet wt)

362.2 ± 11.4

356.0 ± 10.0

MT (pg/g wet wt)
5.1 ±0.6
4.3 ±0.5
The data was obtained from non-transgenic mice (Control, n=6) and 5 representative
transgenic mouse lines as shown in figure 4 (line 738, 742, 782, 776, 777). Three mice
were used from each of the 5 lines and the data was pooled together to give the average
value (MyCat, n=15).

Another unique feature of the model is that among the different transgenic lines,
catalase activity in the heart is elevated from 2- to 630-fold higher than normal. This
provides a useful tool to study the catalase activity-dependence of cardioprotection
against Adriamycin toxicity. It also provides a unique in vivo approach to the importance
of an optimum balance between SOD and catalase in cellular defense against Adriamycin
cardiotoxicity. In particular, SOD activity in the heart is about 4-fold lower than that in
the liver while the catalase activity is about 50-fold lower, suggesting that an imbalance
between the two enzymes may exist in the heart. Therefore, this experimental model
would provide a useful tool to address these two important issues of the catalase-involved
cardioprotection against Adriamycin toxicity.

CHAPTER IV

STUDY II: SUPPRRESSION OF ADRIAMYCIN ACUTE CARDIOTOXICITY BY
OVEREXPRESSION OF CATALASE IN THE HEART OF TRANSGENIC MICE

Adriamycin is an anthracycline antibiotic and one of the most important
anticancer agents. It is effective in treatment of acute leukemias and malignant
lymphomas as well as a number of solid tumors. However, cardiotoxicity is a major
limiting factor for the clinical use of Adriamycin (26). Studies have suggested that
Adriamycin may have at least two mechanisms of action that cause cellular damage. One
mechanism involves generation of oxygen free radicals, the damage from which is
inhibited by free radical scavengers. This appears to play a major role in the development
of cardiomyopathy (16, 197). The other mechanism is mediated by the intercalation of
the drug to DNA and is unaffected by free radical scavengers. This appears to be the
major determinant of Adriamycin cytotoxicity to tumor cells (16).
As described in the Introduction, catalase is a major enzyme involved in the
detoxification of hydrogen peroxide (H20 2). This enzyme catalyzes the conversion of
two molecules of H20 2 to molecular oxygen and two molecules of water. The primary
physiological function of this enzyme is to detoxify the H20 2 produced as a result of
peroxisomal aerobic dehydrogenase reactions. The importance of catalase in providing
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protection against extra-peroxisomal H20 2 is not clear. Studies with isolated
hepatocytes, however, have demonstrated that under conditions of GSH depletion
catalase functions in metabolism of H20 2 produced by the cytochrome P-450-linked
monooxygenase system (125). It is thus possible that under conditions of extreme
oxidative stress, which in most cases involves GSH depletion, catalase may become
important in providing cytoprotection.
Catalase activities are highest in liver and erythrocytes, relatively high in kidney
and adipose tissue, intermediate in lung and pancreas, and very low in heart and brain
(160). It has been shown that catalase activity in the heart is about 2% of that in the
liver of the human (160), the mouse (163), and the rat (161). Several studies have
been undertaken to determine the role of catalase in cardioprotection against oxidative
injuries. Supplementation of perfusion medium with catalase significantly reduced
ischemia-reperfusion injury to the isolated rat heart by detoxifying H20 2 (165). The
role of catalase in metabolism of H20 2 in the heart tissue was also tested directly by
adding H20 2 into perfusion medium (166). Accumulated evidence shows that catalase,
although present at low levels of activity, functions in detoxification of H20 2 in the
myocardium.
It is unknown, however, whether the low catalase activity in the heart is
responsible for the high sensitivity of this organ to oxidative stress. Current
approaches using the isolated heart perfused with catalase have limited application.
Exogenously added catalase may not be able to function intracellularly, but may react
only with H20 2 directly in the perfusion medium. Thus, the relationship between the
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low constitutive catalase activity and the high sensitivity to oxidative stress in the heart
has not been defined.
In the present study, the transgenic mouse model in which catalase is
overexpressed only in the heart was used to determine whether catalase elevation
provides protection against Adriamycin cardiotoxicity.

Lipid peroxidation in the

heart, and serum creatine phosphokinase (CPK) activity were measured in the
Adriamycin-treated transgenic mice and non-transgenic controls. In addition, the atria
isolated from the transgenic mice and non-transgenic controls were used to determine
the effect of catalase on Adriamycin-induced functional changes. The results
demonstrated that overexpression of catalase in the heart provides protection against
Adriamycin cardiotoxicity.
Results
Four transgenic lines were selected to determine the effect of elevated catalase
activity on Adriamycin-induced oxidative damage to the heart. These four transgenic
lines have cardiac catalase activity about 15-, 60-, 100-, and 200-fold higher than
normal. Transgenic mice and non-transgenic controls were treated with a single dose
of Adriamycin at 20 mg/kg. Four days after the treatment, the lipid peroxide products,
malondialdehyde (MDA) and 4-hydroxyalkenals were determined. As shown in Fig.
11, the level of the lipid peroxidation products was markedly elevated by Adriamycin
in non-transgenic mice. This toxic effect of Adriamycin was suppressed in the
transgenic hearts in a catalase activity dependent fashion. The highest protection was
observed in the hearts expressing this enzyme activity about 60- to 100-fold higher than
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normal. However, the transgenic line overexpressing catalase activity about 200-fold
higher than normal demonstrated no protection from Adriamycin.
Adriamycin toxicity was also revealed by elevated serum CPK in non-transgenic
mice (Fig. 12). Catalase overexpression provided essentially the same protection
against CPK release as it did for lipid peroxidation. Again, the protection was roughly
activity dependent except for the line with 200-fold overexpression, which failed to
demonstrate any protection.
Because the loss of protection with 200-fold overexpression of catalase activity
was unexpected, we performed preliminary studies with 500-fold catalase
overexpressing mice (line 756).

Adriamycin increased MDA levels to 93.1 +. 10.9

nmol/gm (n=4) in the transgenic heart and 80.6 _+ 2.2 nmol/gm (n=4) in the nontransgenic heart. The level of serum CPK was 1.70 ±_ 0.15 U/ml (n=4) in the
Adriamycin-treated transgenic mice and 1.50 ±_ 0.20 U/ml (n=4) in the Adriamycintreated non-transgenic mice. These preliminary results suggested that 500 fold higher
levels of catalase may have enhanced Adriamycin-induced lipid peroxidation in the
heart and CPK release from the heart.
Isolated atria (left and right connected) from transgenic mice overexpressing
cardiac catalase activity about 60-fold higher than normal were used to determine the
effect of catalase on Adriamycin-inhibited atrial function. Spontaneous contractions
were recorded. When Adriamycin was added to the incubation buffer, inhibition of
both contraction frequency and contractile force occurred. As shown in Fig. 13, the
catalase overexpressing atrium displayed a marked resistance to the toxic effect of
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Adriamycin. In addition, the function of the transgenic atrium completely recovered
after removal of Adriamycin, but the normal atrium did not. To precisely determine
the effect of Adriamycin on contractile force and heart rate, left and right atria were
separated. The left atrium was paced by a stimulator at a fixed frequency of 4 Hz and
a voltage of 1.5 times the threshold value. As shown in Fig. 14 and Fig. 15, sixty-fold
elevation of catalase activity markedly suppressed Adriamycin-induced changes in
contractile fprce (left atrium) and heart rate (right atrium).
Discussion
Cardiotoxicity has long been recognized as a complicating factor of cancer
chemotherapy with Adriamycin. There are several hypotheses to explain Adriamycin
cardiotoxicity. Among these the free radical hypothesis is the most thoroughly
investigated. Adriamycin undergoes one-electron reduction through a metabolic
activation caused by NADPH-cytochrome-P-450 reductase, or other flavin-containing
enzymes (81). This reduction generates Adriamycin semiquinone free-radical. In the
presence of molecular oxygen, the semiquinone rapidly reduces the oxygen to
superoxide with regeneration of intact doxorubicin. Superoxide is rapidly converted to
hydrogen peroxide spontaneously or by superoxide dismutase. The Adriamycin
semiquinone can then react with the hydrogen peroxide to yield hydroxyl radical (198).
These highly toxic reactive oxygen species react with cellular molecules including
nucleic acids, protein, and lipids, thereby causing cell damage. Most supportive
evidence for this free radical hypothesis has been obtained from in vitro studies
including reports that: 1) Adriamycin increases lipid peroxidation and free radical
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Fig. 11. Adriamycin-induced lipid peroxidation in the hearts of normal and transgenic
mice. The levels of malondialdehyde (MDA) and 4-hydroxyalkenals were measured to
estimate the extent of lipid peroxidation in the tissue. The concentration of the lipid
peroxides in non-transgenic saline-injected mice (Cont, n=15) was 56.8 nmol/g wet wt.
Controls for each transgenic mouse line (saline injection only) showed no significant
difference in the cardiac lipid peroxide level from the non-transgenic controls (data not
shown). Adriamycin significantly (P<0.05) increased the lipid peroxide level in nontransgenic normal mouse hearts (ADR, n=15). Fifteen fold elevation of catalase activity
in the heart slightly decreased the level of Adriamycin-induced lipid peroxides (line 738,
n=8). Sixty (line 742, n=10) or 100 fold (line 776, n=10) elevation significantly inhibited
Adriamycin-induced lipid peroxidation (p<0.05). The level of lipid peroxides in these
hearts was not significantly different from that in the normal saline-treated hearts. Two
hundred fold elevation did not significantly decrease the level of lipid peroxides (line
777, n=10).
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Fig. 12. Adriamycin-induced creatine phosphokinase (CPK) release from the heart.
Serum CPK was measured using a CK-20 kit from Sigma. Sera from the same animals
treated for determination of lipid peroxidation were collected for the CPK measurement.
As shown, Adriamycin significantly increased serum CPK level in the non-transgenic
control mice (ADR). Elevation of catalase in the heart to about 60 (line 742) or 100 fold
(line 776) higher than normal completely inhibited the increase in the serum CPK level
(p<0.05). However, elevation of cardiac catalase activity to about 200 fold (line 777)
higher than normal did not protect against this toxic effect of Adriamycin.
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Fig. 13. Functional changes induced by Adriamycin in the isolated atria (left and right
connected) from normal and transgenic mice (line 742). The transgenic atrium contains
catalase activity about 60 fold higher than the normal control. The atria were incubated
with 100 /xM Adriamycin (final concentration) in the perfusion buffer. Changes in
spontaneous contraction of the atria were recorded at the times before (0 min) and post
Adriamycin treatment (10, 20, and 30 min) as shown. This experiment was repeated 5
times with atria isolated from different animals. The same result was obtained with the
repeated experiments.
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Fig. 14. Effect of catalase elevation on Adriamycin-reduced inotropism. The
transgenic left atria (line 742) contain catalase activity about 60 fold higher than the
non-transgenic control and Adriamycin was added into the incubation buffer to a final
concentration of 100 /iM. The left atria were paced by a fixed frequency of 4 Hz and a
voltage of 1.5 times the threshold value. Time-course of the effect of Adriamycin on
the contractile force of transgenic heart and controls was measured. Contractile force
at the time of Adriamycin addition was set at 100%. This measurement was repeated
three times with atria isolated from different animals and consistent results were
obtained.

% of basal contractile force
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Fig. 15. Effect of catalase elevation on heart rate reduced by Adriamycin. The
transgenic right atria (line 742) contain catalase activity about 60 fold higher than the
non-transgenic control and Adriamycin was added into the incubation buffer to a final
concentration of 100 fiM. The spontaneous beating of right atria was recorded. Timecourse of the effect of Adriamycin on the contraction frequency of transgenic heart and
controls was measured.

Contraction frequency at the time of Adriamycin addition was

set at 100%. This measurement was repeated three times with atria isolated from
different animals and consistent results were obtained.
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production in the heart tissue (199); 2) free radical scavengers such as N-acetylcysteine
(200), vitamin E (16,74), superoxide dismutase (74) and catalase (16) decrease the
severity of Adriamyicn-induced oxidative damage; 3) suppression of antioxidant
activities enhances Adriamycin toxicity in cultured cardiac cells (201). However,
contradictory results have been reported. Some in vivo studies have shown that free
radical scavengers failed to prevent cumulative Adriamycin cardiotoxicity (95,202).
Why have some in vivo studies failed to find antioxidant protection against
Adriamyicn cardiotoxicity? Under in vivo conditions, three major problems
complicate data interpretation: 1) it is impossible to maintain constant plasma
antioxidant concentrations and to accurately predict the target tissue concentrations; 2)
metabolic activation and inactivation by multiple metabolic organs such as liver and
kidney would greatly affect the efficacy of the antioxidants; and 3) high molecular
weight antioxidants such as superoxide dismutase and catalase are unlikely to be
transported into intracellular compartments. To overcome the shortcomings of these
earlier in vivo studies, we produced a unique transgenic model.

As described in the

study 1, in this model intracellular catalase activities are maintained at permanently
elevated levels specifically in the heart of each transgenic line. Other antioxidant
systems were found to be unaffected in the catalase overexpressing heart. Electron
microscopic studies (data not shown) demonstrated increased numbers of peroxisomes
in transgenic hearts, suggesting that a significant amount of elevated catalase is
contained in peroxisomes.

82

There are at least two major factors responsible for the selective cardiotoxicity
of Adriamycin: an unusually high level of drug accumulation (203,204) and weak
antioxidant defense mechanisms in cardiac muscle cells (161,163). Among the
important antioxidant enzymes catalase activity in the heart is specially low(160-163).
The results obtained from this study clearly demonstrate that elevation of catalase
activity to an optimum level provides protection against Adriamycin-induced cardiac
injury. This suggests that low catalase activity in the heart is a major factor
responsible for the high sensitivity of the heart to Adriamycin-induced damage.
Because catalase is a major enzyme that metabolizes H20 2 in the cell and this enzyme
has no activity to react with Adriamycin and its metabolites, the results thus provide
direct evidence to support the oxidative injury hypothesis for Adriamycin.
Lipid peroxidation is a major cardiotoxic indicator of Adraimycin, particularly
under the conditions of acute exposure. It has been found that Adriamycin more
selectively induces this oxidative damage to the heart relative to other organs such as
the liver in mice (205). We have determined the lipid peroxide levels in the heart
induced by Adriamycin as a function of time (days). We found that at the selected dose
(20 mg/kg) lipid peroxide levels in the heart reach a peak value on the fourth day after
the drug treatment (data not shown). This peak value coincides with high serum CPK
activity at the same time, which is in agreement with previous studies (206). Because
the elevation in serum CPK results from the myocardial cell membrane damage due to
lipid peroxidation, the increased serum CPK activity has been used as another indicator
of Adriamyicn-induced heart damage (206,207). The results obtained from this study
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show that elevated catalase activity protects from Adriamycin-induced lipid
peroxidation, which correlates with the protection against CPK release. In both cases,
sixty- or 100-fold elevation of catalase activity provides maximum protection.
Functionality of the isolated mouse atrium has been increasingly used as a fast
screening method for determination of cardiotoxicity induced by Adriamycin (193).
Usually, the mouse atrium is incubated with the tested compound and changes in
contractile force and heart rate are recorded as a measurement of cardiotoxicity. It has
been shown that Adriamycin depresses the functionality of isolated mouse atria (208210). Adriamycin-induced functional changes in the isolated atria were observed in the
present study. Both contractile force and heart rate were suppressed. Sixty-fold
elevation of catalase activity markedly depressed this effect of Adriamycin on cardiac
function. This result demonstrates that Adriamycin-induced cardiac functional
alterations most likely result from reactive oxygen species and that the severity of the
functional alterations is associated with catalase levels.
In the present study we found that 200-fold elevation of catalase activity in the
heart did not provide protection against Adriamycin toxicity and 500-fold elevation
may even enhance the Adriamycin cardiotoxicity. The same observation has also been
reported in vitro. For instance, transfection of L cells with a human catalase cDNA
elevated catalase activity by 100-fold. These catalase-enriched cells, however, were
more sensitive rather than resistant to the cytotoxicity of paraquat, bleomycin, and
Adriamycin than the untransfected cells from which they were derived (174). At least
two mechanisms have been proposed for the increased sensitivity of the high catalase
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containing cells: (1) imbalance between SOD and catalase (172,175); (2) chelation of
heme iron by catalase and release of iron after degradation of catalase. It has been
shown that iron-Adriamycin complex is toxic (211). The relevant mechanism for the
effect observed in this study is unknown. However, the results clearly demonstrated
that elevation of cardiac catalase activity to an optimal level provides protection against
Adriamycin acute cardiotoxicity.

CHAPTER V

STUDY III: INHIBITION OF ADRIAMYCIN CHRONIC CARDIOTOXICITY BY
OVEREXPRESSION OF CATALASE ON THE HEART OF TRANSGENIC MICE

The cardiotoxic effects of Adriamycin can be subdivided into two categories:
acute effects and chronic effects. The acute effects are characterized by hypotension,
tachycardia, and various arrhythmias which develop within minutes after iv
administration and return to normal within a few days. These acute toxic effects are not
dose-dependent and do not contraindicate further therapeutic application of the drug. In
contrast, the chronic cardiomyopathy induced by Adriamycin is the major drawback of
the drug in cancer chemotherapy. This chronic cardiomyopathy is manifested by the
insidious onset of severe, often fatal congestive heart failure. Therefore, it is important to
reduce the chronic cardiomyopathy of Adriamycin.
There is growing evidence in the literature that production of oxygen free radicals
is a primary mechanism in Adriamycin cardiotoxicity. Adriamycin can be reduced by
cellular flavoenzymes to a semiquinone free radical. This Adriamycin semiquinones then
gives rise to oxygen free radicals that can initiate cellular damage if they overwhelm the
antioxidant defense mechanisms. Destruction of toxic reactive oxygen radicals in the
cytosol and within mitochondria is achieved primarily by three enzymes: glutathione
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peroxidase (GSHpx), superoxide dismutase (SOD), and catalase. It has been found that
these enzyme activities are lower in the heart than in several other organs, including the
liver and kidney (163). Addition of catalase and SOD has provided cardioprotection
under certain pathological conditions(212). In the acute study, the two enzymes given
together provided better protection than when either enzyme was given alone (213).
However, the protective activity elicited by SOD and catalase does not extend to long
term survival. This appears to be related to the instability of the oxoygenously added
antioxidants in the body, unpredicted pharmacokinetics, and their exclusion from the
cells. To overcome these limitations, a stable rather than short-term approach is more
appropriate for these studies.
In this study, we used the unique transgenic mouse model in which catalase was
constitutively overexpressed in the heart tissues. The role of catalase in protection against
Adriamycin-induced chronic cardiotoxicity was evaluated by examining morphological
changes in catalase-enriched transgenic heart and controls treated with Adriamycin.
Results
Three transgenic mouse lines in which catalase are 15-, 60-, and 100-fold higher
than normal were selected. Transgenic mice and non-transgenic controls were injected iv
with Adriamycin at a dose of 9 mg/kg every other week, for a total of five injections. On
the second day after the last injection, the animals were sacrificed and Adriamycininduced cardiac morphological changes were determined by light and electron
microscopy. The effect of Adriamycin on body weight was measured every week during
Adriamycin treatment.
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The body weight gain of the mice during the 8 weeks of treatment is shown in
Fig. 16. There was a decrease in mean body weight gain in control mice receiving
Adriamycin compared to the saline-injected controls after the 8 week of treatment.
Elevation of cardiac catalase tol5-, 60-, and 100-fold significantly protected against
Adriamycin-decreased body weight gain. There was no significant difference in body
weight gains among these three transgenic mouse lines treated by Adriamycin. Mortality
was encountered only in control animals treated with Adriamycin; about 15% (3 out of
19) control mice receiving Adiamycin died during the treatment. No deaths were
observed in the groups of transgenic mice receiving Adriamycin. The results indicate that
the elevation of catalase provided protection against Adriamycin-induced mortality and
inhibited the effect of Adriamycin-decreased body weight gain.
Histologic evidence of myocardial damage was evident in mice that died during or
after Adriamycin treatment. Ventricular myocardium from a control mouse is shown in
Fig. 17. The lesions observed by light microscopy in myocardium of control mice
receiving Adriamycin were focal myocyte degeneration, interstitial edema, and interstitial
and intramyocytic vacuolization (Fig. 18). Focal myocyte degeneration was identified by
the presence of densely eosinophilic cells lacking cross-striations that gave a positive
PAS reaction following diastase digestion. The score of the myocardial lesions resulting
from Adriamycin administration are piesented in Table 3. Fifteen-fold elevation of
cardiac catalase appeared to protect against Adriamycin-induced cardiotoxicity, but there
were no significant differences between control and the transgenic groups. However, 60-
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fold and 100-fold elevation of cardiac catalase markedly depressed the morphological
effects of Adriamycin (p<0.01).
EM studies were performed simultaneously with the above described light
microscopic studies and results are shown in Figs. 19-22. Myocardial fine structural
changes were observed in the control mice treated with Adriamycin. Moderate nuclear
chromatin margination with many pieces of coarse chromatin clumping was observed.
Mitochondria showed severe swelling with membrane disruption, cristae disappearance
and matrix clearing. Myelin figures were also observed. Sarcoplasmic reticula and ttubular were slightly dilated. Adriamycin-induced subcellular changes in the transgenic
mice were much less severe in comparison to that in the control mice. Minor
mitochondrial swelling was observed with intact mitochondrial membrane and cristae. A
small degree of myofibrillar lysis with no disruption of the ordered parallel array and no
myelin figure was found.
Discussion
Adriamycin induced chronic cardiomyopathy is the major drawback of the drug in
cancer chemotherapy. This chronic cardiomyopathy produces significant morbidity and
mortality (214). The primary cardiac morphological changes observed in patients with
chronic Adriamycin treatment are cardiac dilation, myocyte degeneration and atrophy,
interstitial edema, and fibrosis (215). The degeneration of cardiac muscle cells is
associated with myofibrillar loss and cytoplasmic vacuolization (215). This chronic
cardiomyopathy is manifested by the insidious onset of severe, often fatal congestive
heart failure. Therefore, it is important to reduce the chronic cardiomyopathy.
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Fig .16. Effect of Adriamycin on the body weight gain of transgenic and control mice.
Transgenic mice and non-transgenic controls were injected iv with Adriamycin at dose of
9 mg/kg every other week, for total of five injections. Mean body weight gain expressed
at the percentage of initial weight.

% of initial weight
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Fig. 17. Light micrograph o f myocardium o f non-transgenic control mice.
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Fig. 18. Light micrography o f myocardium showing the effect o f Adriamycin-induced

cardiotoxicity.
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Table 3. Histological evaluation of the cardiac lesions in control and My Cat transgenic
mice chronically treated with Adriamycin
MyCat
Control

15-fold

60-fold

100-fold

Severity

1.60 ±0.2

1.3 ±0.05

1.14 ±0.06

1.04 ±0.04

Extension

1.72 ±0.06

1.60 ±0.05

1.00 ±0.04*

0.97 ±0.11*

Total cardiotoxi
city score

2.77 ± 0.40

2.10 ± 0.13

1.14 ±0.08*

1.00 ±0.08*

*p<0.01 with respect to control mice.

A recent review by Herman et al.(216) has extensively summarized current
existing approaches to reduce the cardiotoxicity of anthracyclines. These attempts to
ameliorate anthracycline cardiotoxicity include: (1) decreasing myocardial
concentrations of anthracyclines and their metabolites, (2) developing less cardiotoxic
analogues, and (3) concurrently administering other drugs that will block or overcome
the toxic effects of anthracyclines on the myocardium.
To decrease myocardial concentrations of anthracyclines clinicians have applied
methods including alternative dosing regimens, slowly infusing the drug to keep plasma
concentrations low, and/or binding the drug to carrier molecules to decrease the
availability of the drug to myocytes. Alternatively, a considerable effort has been
directed to the synthesis and development of new compounds that will retain significant
anticancer activity while decreasing cardiac toxicity. Finally, many substances have
been tested experimentally as potential cardiac protective agents which can be
concurrently administered with anthracyclines. These substances include free
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Fig. 19. Electron micrograph o f myocardium o f non-transgenic control mice. Cross-

section, X 6000.
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Fig. 20. Electron micrograph o f myocardium o f non-transgenic control mice.

Longitudinal-section, X 6000.
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Fig. 21. Electron micrograph showing myocardial morphological changes induced
bychronic treatment of Adriamycin. Cross-section, X 6000.
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Fig. 22. Electron micrograph showing myocardial morphological changes induced by
chronic treatment of Adriamycin. Longitudinal-section, X 6000.
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radical scavengers, calcium channel blockers, histamine and catecholamine blockers,
cardiac glycosides, carnitine, and EDTA derivatives. These approaches, however,
have achieved limited success.
Although the mechanism of Adriamycin-induced cardiotoxicity has not yet been
established, recent evidence suggests that Adriamycin forms reactive oxygen free radical
species that may oxidize cellular components such as cell membrane components leading
to cardiomyopathy. Adriamycin produces free radicals that damage myocardial tissue by
nonspecific oxidation of membrane and cytosol molecules, eventually leading to cell
death. Destruction of toxic reactive oxygen radicals in the cytosol and within the
mitochondria is achieved primarily by three enzymes: glutathione peoxidase (GSHpx),
superoxide dimutase (SOD), and catalase. It has been found that these protective enzyme
activities are lower in the heart than in several other tissues (163). Addition of catalase
and SOD has provided cardioprotection under certain pathological conditions, including
myocardial ischemia. The effects of treatment with two of these protective enzymes on
Adriamycin toxicity were elucidated in mice and rats (212). Increased survival of the
mice treated with SOD (16 mg/kg, ip) after a single 13.5 mg/kg (ip) dose of Adriamycin
(45% survival with SOD and Adriamycin campared to 30% survival with Adriamycin
alone) was observed. At higher Adriamycin dose (15 mg/kg) survival increased from
12% (Adriamycin alone) to 40% (SOD and Adriamycin). In a second study rats were
dosed with Adriamycin given either chronically (4 mg/kg/wk for 3 weeks) or acutely (a
single dose of 10 mg/kg) and simutaneously treated with catalase (1 mg/kg/day), SOD (1
mg/kg/day) or both. The SOD decreased and catalase increased survival in animals given
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the 3 doses of Adriamycin. Survival increased further when SOD and catalase were
given together. Some attenuations in myocardial alterations also occurred. In the acute
study, the two enzymes given together provided better protection than when either
enzyme given alone (213). However, the protective activity elicited by SOD and catalase
does not include long-term survival and appears to be related to many unstable factors as
described before. To overcome the shortcomings of these in vivo studies, we used the
unique transgenic mouse model that was produced in this laboratory. As described in
Study 1, in this model intracellular catalase activities are maintained at permanently
elevated levels which are specific to the heart of each transgenic line. This unique model
provides an unequivocal experimental approach to precisely determine the role of catalase
in myocardial protection against Adriamycin chronic toxicity in vivo.
The results of this investigation showed that the FVB mice are sensitive to the
cardiotoxic effects of repeated iv injections of low dosages of Adriamycin. The
cumulative dosage of 45 mg/kg reduced body weight gain and produced typical
anthracycline cardiomyopathy in the control mice. The myocardial lesions described in
this investigation were similar to those that occured with chronic Adriamycin
administration in humans (22), rabbits (41,217), and rats (218). The transgnenic mice in
which catalase was elevated to 60-, and 100-fold higher than normal showed markey
resistance to the reduction of body weight gain induced by Adriamycin. These transgenic
mice were also protected from Adriamycin induced cardiac morphological changes.
These results demonstrated that Adriamycin-induced cardiomyopathy most likely
resulted from enhanced generation of reactive oxygen free radicals and toxic lipid
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peroxidation and the severity of the morphological alteration was associated with cardiac
catalase levels. The data also suggested that the transgenic mouse model provided an
ideal tool for the chronic studies regarding the role of antioxidants in protection against
Adriamycin cardiotoxicity.

CHAPTER VI

STUDY IV : REPRESSION OF HYPOXIA-REOXYGENATION INJURY IN THE
CATALSE OVEREXPRESSION HEART OF TRANSGENIC MICE

Ischemia-reperfusion causes depressed myocardial functional changes associated
with deleterious morphological alterations, leading to heart failure and cell death (219).
Mechanisms by which this injury occurs are not well defined. Studies using antioxidants
such as superoxide dismutase (SOD) and catalase suggest that oxidative stress and burst
of free radical production are important mediators of the myocardial damage (220). The
available evidence at present indicates that reperfusion arrhythmias and myocardial
stunning result at least in part from oxygen radicals (221, 222). Myocardial infarction or
cell death may also relate to reactive oxygen radicals (223).
Because catalase is a major enzyme involved in the detoxification of hydrogen
peroxide (H20 2) and the activity of catalase per g tissue in the heart is very low, the high
sensitivity of the heart to hypoxia-reoxygenation may result from its less efficient
hydrogen peroxide detoxification system. Several studies have been undertaken to
determine the role of catalase in cardioprotection against oxidative injuries.
Supplementation of perfusion medium with catalase significantly reduced ischemiareperfusion injury to the isolated rat heart by detoxifying H20 2 (165). The role of catalase
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in the metabolism of H20 2 in the heart tissue was also tested directly by adding H20 2 into
perfusion medium (166). Accumulated evidence shows that catalase, although present at
low levels of activity in the heart, functions in detoxification of H20 2 in the myocardium.
However, current approaches using the isolated heart perfused with catalase have limited
application. Exogenously added catalase may not be able to function intracellularly,
because of its exlusion from the cells due to its high molecular mass. Furthermore, it is
difficult to prolong the catalase perfusion procedure, if that should be an appropriate
approach. Thus, the relationship between the low constitutive catalase activity and the
high sensitivity to oxidative stress in the heart cannot be defined.
The transgenic mouse model in which catalase is overexpressed only in the heart
would be a useful tool to address the role of catalase in cardiac protection against
hypoxia-reoxygenation injury to the heart.. In this study, we determined the effect of
catalase elevation on hypoxia-reoxygenation induced damage to isolated atria.
Functional alterations and morphological changes of the atria under hypoxiareoxygenation conditions were examined. The results demonstrate that overexpression of
catalase in the heart provides protection against hypoxia-reoxygenation induced cardiac
injury.
Results
Spontaneous contractions of the isolated atria (combined left and right) were
recorded when a mixture of 95% 0 2-5% C 02 was bubbled into the perfusion chamber.
As shown in Fig. 23, transgenic atrium and normal control displayed similar contractions
at time 0. Hypoxia was then induced by gassing the perfusion buffer with 95% N2-5%
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C 0 2 (20 mmHg) at 37°C for 240 min. Reoxygenation was done by gassingwith 95% 0 25% C 0 2 (20 mmHg). The contractile force and frequency of both atria were gradually
suppressed by hypoxia. However, the transgenic atrium showed marked resistance to this
hypoxia-induced functional change. The transgenic atrium extensively recovered its
normal contraction upon reoxygenation. However, the normal atrium displayed abnormal
contractions, arrhythmia, a typical reperfusion injury.
To precisely determine the effect of elevated catalase on atrial functional
alterations induced by hypoxia-reoxygenation, left atrium was separated from right
atrium. Cardiac inotropy (contractile foice) and chronotropy (contraction rate) were
recorded from left and right atria, respectively. As shown in Fig. 24 and Fig. 25, both
contractile force and frequency were dramatically depressed under hypoxia in either
normal or transgenic mouse atria. However, the transgenic atria showed significant
resistance against hypoxia-induced decrease in frequency Upcn reoxygenation, both
force and frequency partially recovered. The transgenic atria, however, displayed much
better recovery than the normal atria. Particularly, a gradual decrease in frequency with
arrhythmia (as shown in Fig. 23) was observed in the normal atria after reoxygenation,
while a stable unchanged frequency remained in the transgenic atria.
Morphological studies showed that the myocardial cells of both left and right atria
(Figs. 26-31) subjected to hypoxia and reoxygenation in normal FVB mice showed
margination and coarse clumping of the chromatin, mitochondrial swelling and
disappearance of crstae, often leaving the remnants of the original structure and myelin
figures. The matrix of the mitochondria became translucent. Some myocardial cells
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showed marked cell swelling, the sarcolemma exhibited large empty bleb-like spaces and
small defects in plasma membrane. The basal lamina appeared to be separated from the
surface bilayer membrane. Vesiculation and disruption of the sarcoplasmic reticulum
were obvious. Hypoxic vacuoles were frequently observed. The myofibril between
contraction bands showed partially broken Z-line and a wispy I band. However, in
catalase-transgenic mouse atria, these changes above were only rarely seen in either left
or right atrium.
Discussion
Myocardial injury due to ischemia-reperfusion has been extensively studied. This
injury results at least in part from reactive oxygen radicals, although the exact mechanism
by which the pathogenesis occurs is at present unknown. Recent studies have shown
myocardial protection against ischemia-reperfusion injury and changes in gene
expression occur after whole body heat stress (224-228). For example, reduced infarct
size in vivo (226,229) and in vitro (227) due to ischemia-reperfusion has been shown 24
hr after whole body temperature elevation to 42°C for 15 min. This whole body heat
stress procedure also enhanced postischemic contractile function in vitro (224, 225,228).
The exact nature of this induced protection is unclear. A number of studies (224,225),
however, demonstrated that alterations in myocardial antioxidant systems may be
involved in this process.
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Fig. 23. Functional changes induced by hypoxia-reoxygenation in the isolated atria from
normal and transgenic mice. The transgenic atrium contains catalase activity about 60fold higher than normal. The atria were incubated under the condition described in the
Materials and Methods. At time 0, hypoxia was introduced and lasted for 60 min, then
oxygen was re-introduced and spontaneous contraction was recorded for the entire period
of hypoxia-reoxygenation. This experiment was repeated five times with the atria
isolated from different animals and the same result was obtained as the representative.
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Fig. 24. Effect of catalase elevation (60-fold higher than normal) on reduction in force
induced by hypoxia and reoxygenation. The left atrium of transgenic and non-transgenic
mice were subjected to 60 min hypoxia and 240 min reoxygenation. The left atrium was
paced by a fixed frequency of 4 Hz and a voltage of 1.5 times the threshold value. Timecourse of the effect of hypoxia-reoxygenation on the contractile force of transgenic heart
and controls was measured. Contractile force at the time that hypoxia was introduced
was set at 100%. This measurement was repeated 6 times with atria isolated from
different animals and the data are presented as mean + SD values.

114

0

60

240

300

115

Fig. 25. Effect of catalase elevation (60-fold higher than normal) on reduction in heart
rate induced by hypoxia and reoxygenation. The right atrium of transgenic and nontransgenic mice was subjected to 60 min hypoxia and 240 min reoxygenation.
Spontanous contraction was recorded. Time-course of the effect of hypoxiareoxygenation on the contraction frequency of transgenic heart and controls was
measured. Contraction frequency at the time that hypoxia was introduced was set at
100%. This measurement was repeated 6 times with atria isolated from different animals
and the data are presented as mean + SD values.
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Fig. 26. Electron micrograph o f left atrium o f non-transgenic control.
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Fig. 27. Hypoxia-reoxygenation induced myocardial morphological changes o f left
atrium o f non-transgenic control.
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Fig. 28. Hypoxia-reoxygenation induced myocardial morphological changes o f left
atrium o f transgenic mouse.
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Fig. 29. Electron micrograph o f right atrium o f non-transgenic control.
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Fig. 30. Hypoxia-reoxygenation induced myocardial morphological changes of right
atrium of non-transgenic control.
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Fig. 31. Hypoxia-reoxygenation induced myocardial morphological changes of right
atrium o f transgenic mouse.
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Catalase is increased within the myocardium 24 hr after whole body heat stress
(225). This enzyme is highly relevant to protection because of its role in detoxification of
hydrogen peroxide. Supplementation of perfusion medium with catalase significantly
reduced ischemia-reperfusion injury to the isolated heart (165), and inhibition of catalase
can at least partially abolish post-heat stress protection when contractility is used as the
endpoint of injury (14).
Catalase is, however, not the only protein that is elevated after heat stress. An
inducible member of the hsp70 family shows marked changes 24 hr after heat stress (224229). Numerous studies have suggested the possible involvement of HSP70 in
myocardial protection. For example, elevated levels of the highly inducible member of
the HSP70 family were associated with improved post-ischemia recovery (230-232) and
with reduction in infarct size in hearts (233). There appears to be a correlation between
the amount of the inducible HSP70 and the extent of myocardial protection (234). A
more direct demonstration of the involvement of the inducible HSP70 in myocardial
protection against ischemic injury comes from two recent studies using transgenic mice
overexpressing the inducible HSP70 (235,236). Both studies showed a marked resistance
to ischemia-reperfusion injury in the isolated hearts from the HSP70 overexpressing
transgenic mice.
In the present study, direct evidence regarding the importance of catalase in
myocardial protection against hypoxia-reoxygenation was obtained. We took advantage
of elevation of catalase specifically in both atria and ventricles of the transgenic mice and
directly monitored atrial functional alteration under hypoxia-reoxygenation. Importantly,
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the isolated atria allowed precise determination of the effects of hypoxia and
reoxygenation on heart rate and contractile force. The results demonstrated that hypoxiareoxygenation reduces contractile force and frequency in the isolated atria.
Reoxygenation resulted in arrhythmia, a typical reperfusion injury observed in the heart
both in vitro and in vivo. The catalase overexpressing atrium displayed a marked
attenuation in the hypoxia-reoxygenation induced reduction of contractile force and
contraction frequency, and abolished the reoxygenation-induced arrhythmia.
Corresponding to these protective effects on functional alterations induced by hypoxiareoxygenation, catalase overexpression in the heart also markedly suppressed the
morphological changes as examined by electron microscopy.
Other experimental approaches have involved the use of catalase to study its role
in cardiac protection against ischemia-reperfusion injury. Most of these studies either
supplemented catalase in vivo or added catalase in perfusion buffer in vitro. Three major
problems complicate data interpretation from these studies: 1) it is impossible to maintain
constant plasma antioxidant concentrations and to accurately predict the target tissue
concentrations; 2) metabolic activation and inactivation by multiple metabolic organs
such as liver and kidney would greatly affect the efficacy of the antioxidant; and 3) high
molecular weight catalase is unlikely to be transported into intracellular compartments.
To overcome the shortcomings of these earlier studies, we utilized the unique transgenic
model in the present study. In this model intracellular catalase activities are maintained
at permanently elevated levels specifically in the heart without alterations in any other
antioxidant systems. The experiments with the card'ac catalase overexpressing
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transgenic mouse heart thus strongly suggest that an elevated level of catalase plays a role
in cell protection against reactive oxygen induced damage. This study also suggests that
low catalase activity in the heart is a major factor responsible for the high sensitivity of
the heart to ischemia-reperfusion injury. In addition, because catalase is a major enzyme
that metabolizes H20 2 in the cell and this catalase activity is quite specific, the results
thus provide direct evidence to support the oxidative injury hypothesis for ischemiareperfusion.
In summary, catalase overexpression in the heart of transgenic mice inhibited
hypoxia-reoxygenation induced reduction in contractile force and heart rate, and
eliminated reoxygenation-induced arrhythmia. The catalase overexpressing transgenic
atria were also highly resistant to hypoxia-reoxygenation induced morphological
alterations as examined by electron microscopy. The results thus provide direct evidence
that catalase is significantly involved in cellular protection against hypoxia-reoxygenation
cardiotoxicity.

CHAPTER VII

SUMMARY OF DISCUSSION
Adriamycin is widely used in clinical medicine for cancer chemotherapy. It has a
broad range of antitumor activities including soft tissue sarcomas, breast cancer, small
cell carcinoma of the lung, and acute leukemias. Unfortunately, the clinical use of
Adriamycin has been limited by its undesirable side effects, especially cardiotoxicity.
The cumulative dose-dependent cardiomyopathy limits the total dose of Adriamycin that
can be administrated in the treatment of neoplastic diseases(30). The prevention of
Adriamycin cardiotoxicity without interferences with the drug's antitumor activity would
be of considerable consequence in achieving additional therapeutic benefit from this
agent.
Adriamycin-induced perturbation in myocardial cells includes mitochondrial
lesions, disruption of myofibrils, degeneration of Z-band, and eventually myocyte
dropout (22,41). These lesions are accompanied by or eventually lead to myocardial
dysfunction, which will manifest as heart failure in some patients. Although these
morphological and functional descriptions of Adriamycin's cardiotoxicity have been
known for many years, the mechanism of production of these lesions and the reason for
the selective toxicity to the heart remain unknown. One of the most likely mechanisms
for the cytotoxicity of Adriamycin is the production of free radicals in the heart which
results in lipid peroxidation, a cause of Adriamycin-induced cardiomyopathy (199). This
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free radical mechanism has been supported by the evidence including reports that: 1)
Adriamycin increases lipid peroxidation and free radical production in the heart tissue
(199); 2) free radical scavengers such as N-acetylcysteine (200), vitamin E (16,74),
superoxide dismutase (74) and catalase (16) decrease the severity of Adriamycininduced oxidative damage; 3) suppression of antioxidant activities enhances Adriamycin
toxicity in cultured cardiac cells (201). However, contradictory results have been
reported. Some in vivo studies have shown that free radical scavengers failed to
prevent cumulative Adriamycin cardiotoxicity (95,202).
Intact cells regulate redox state by several enzymatic processes in which
glutathione peroxidase (GSHpx) and catalase are of major importance in protecting cells
from oxidative damage by free radicals. However, both enzymes are low in the heart, in
particular, catalase activity in the heart is about 2% of that in the liver. The relative
deficit in cardiac catalase may be a factor responsible for the high sensitivity of the heart
to oxidative damage. This hypothesis has been continually tested using isolated hearts
and other in vitro models (165-168). But current approaches provide only in vitro
understanding of Adriamycin acute cardiotoxcity. To provide an unique in vivo model
for studying both acute and chronic Adriamycin cardiotoxicity, we developed a
transgenic mouse model in which catalase was overexpressed specifically in the heart
tissue. Characterization of the transgenic mice shows that only catalase, not other
antioxidant components, was overexpressed specifically in the heart, in both atria and
ventricles. This enzyme activity was not altered in any of other organs including liver,
kidneys, lungs, and skeletal muscles of any of the five tested transgenic mouse lines.
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The model is ideal to determine the role of catalase in protection against Adriamycininduced heart injury.
Another unique feature of the model is that among the different transgenic lines,
catalase activity in the heart is elevated from 2- to 630-fold higher than normal. This
certainly provides a useful tool to study the catalase activity-dependence of
cardioprotection against Adriamycin toxicity. It also provides a unique in vivo
approach to the importance of an optimum balance between SOD and catalase in
cellular defense against Adriamycin cardiotoxicity. In particular, SOD activity in the
heart is about 4-fold lower than in the liver while the catalase activity is about 50-fold
lower, suggesting that an imbalance between the two enzymes may exist in the heart.
Chronic cumulative cardiotoxicity is the limiting factor for the clinical
application of Adriamycin. However, current approaches have limitations to address
the relationship between antioxidants and Adriamycin toxicity. Maintaining a constant
level of exogenously added antioxidants in the heart is impossible. Moreover, high
molecular weight antioxidants such as catalase can not be transported into cells. As
described in study 3, the model thus provided a unique approach for the chronic studies
regarding the role of antioxidants in protection against Adriamycin cardiotoxcity.
We have determined the effects of varying catalase activities on the acute and
chronic toxicities of Adriamycin by examining biochemical, morphological, and
functional alterations of the hearts.
Creatine phosphokinase (CPK) is primarily located in skeletal muscles and heart
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muscle. Damage to these tissues results in the release of increased levels of CPK into
the blood. Cardiac muscle injury following myocardial infarction results in a rise in
serum CPK activity, reaching a peak of 7- to 12- times the upper limit of normal within
18 to 30 hours. Therefore, measurement of serum CPK activity is used as a diagnostic
tool to detect myocardial infarction and various forms of muscle disease. Elevation of
serum CPK has been used as an indicator of Adriamycin-induced heart damage
(206,207). We found that at the selected dose (20 mg/kg ip) serum CPK activity was
significantly increased in the control mice. The elevation of serum CPK activity was
associated with increased lipid peroxidation levels. Trangenic mice in which catalase
activities are 60- and 100-fold higher than normal provided protection against
Adriamycin-induced CPK release from the hearts. However, the transgenic line
overexpressing catalase 200 fold higher than normal demonstrated no protection from
Adriamycin.
Isolated atria from non-transgenic mice and transgenic mice overexpressing
cardiac catalase 60-fold higher than normal were used to determine the effect of
Adriamycin on atrial function. Adriamycin suppressed both contractile force and
contraction frequency of control heart. Sixty-fold elevation of catalase activity
markedly depressed this functional effect of Adriamycin. This result demonstrates that
Adriamycin-induced cardiac functional alterations most likely result from reactive
oxygen species and that the severity of the functional alterations is associated with
catalase levels.
Adriamycin-induced cardiac morphological changes in animal models and
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human patients have been well documented (214-216). The primary cardiac
morphological changes include cardiac dilation, myocyte degeneration and atrophy,
intestitial edema, and fibrosis (215). The degeneration of cardiac muscle cells is
associated with myofibrillar loss and cytoplasmic vacuolization (215). Electron
microscopic studies have shown that the vacuolization of the cytoplasm is mainly due to
pronounced swelling of the tubules and cisterns of the sarcoplasmic reticulum (216).
The mitochondria have been found to show a variety of changes, including swelling,
disruption, alterations in the density of the matrix, and formation of myelin figures.
We determined the effect of elevated catalase activities in the heart of trangenic mice
on Adriamycin-induced morphological changes and found that 60-fold and 100-fold
elevation of cardiac catalase attenuated the morphological changes in both acute and
chronic treatment of Adriamycin.
It has been shown that Adriamycin undergoes one-electron reduction through a
metabolic activation caused by NADPH-cytochrome-P-450 reductase, or other flavincontaining enzymes (11). This reduction leads to a free-radical semiquinone, which in
turn can generate reactive reduced oxygen species such as superoxide anion (0 2),
hydrogen peroxide (H20 2), and hydroxyl radical (HO ) (81). These highly toxic
species may react with cellular molecules including nucleic acids, protein, and lipids,
thereby disrupting them. More importantly, the oxygen radical chain reaction leads to
lipid peroxidation at the plasma membrane, which is considered to be responsible for
lethal membrane damage (238). Strong evidence is presently available for the
involvement of oxidative membrane damage in the cardiac toxicity of Adriamycin
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(197). Therefore, we determined that the effect of elevated catalase activities on
Adriamycin induced lipid peroxidation in the heart with the acute treatment. We found
that at the selected dose (20 mg/kg) lipid peroxide levels in the heart reach a peak value
on the fourth day after the drug treatment (data not shown). This peak value coincides
with high serum CPK activity, which is in agreement with previous studies (206). The
elevated catalase activity protects from Adriamycin-induced lipid peroxidation, which
correlates with the protection against CPK release. Sixty- or 100-fold elevation of
catalase activity provides maximum protection. The results obtained from this study
suggests that elevation of cardiac catalase provides protection against Adriamycin
cardiotoxicity by the mechanism of detoxification of oxidative stress and inhibiting
lipid peroxidation.
The results obtained from our studies clearly demonstrated that elevation in
catalase activity to an optimum level provided protection against Adriamycin-induced
cardiac injuries. Low antioxidant capacity in the heart is therefore a major factor
responsible for the high sensitivity of the heart to Adriamycin-induced damages. The
results not only illustrate the importance of catalase in cardiac protection against
Adriamycin toxicity, but also further suport the oxidative injury hypothesis of
Adriamycin.
The relative deficit in the antioxidant activity of the heart may be responsible
for its unusual sensitivity to not only Adriamycin but also other toxic agents. The
catalase-enriched transgenic mouse model would provided a valuable experimental
approach to understanding mechanisms of other cardiac oxidative damage. Myocardial
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injury due to ischemia-reperfusion has been extensively studied. Although the exact
mechanism by which the pathogenesis occurs is unknown, this injury results at least in
part from reactive oxygen radicals. There is argument regarding whether low catalase
activity in the heart generally makes the heart more sensitive to a variety of ischemiareperfusion injuries. Our transgenic mouse model was used to determine the effect of
elevated catalase on hypoxia-reoxygenation induced damage to isolated atria.
Functional alterations and morphological changes of the atria under hypoxiareoxygenation conditions were examined. The results demonstrated that the catalase
overexpressing atrium displayed a marked attenuation in the hypoxia-reoxygenation
induced reduction of contractile force and contraction frquency. Corresponding to these
protective effects on functional alterations induced by hypoxia-reoxygenation, catalase
overexpression in the heart also markedly suppressed the morphological changes as
examined by electron microscopy. The results thus provide direct evidence that catalase
is important in cellular protection against hypoxia-reoxygenation cardiotoxicity. The
model is thus ideal to study the mechanism of many cardiac oxidative injuries.

CHAPTER VIII

FUTURE AREAS OF RESEARCH
In our studies we found that 200 fold elevation of catalase activity in the heart
did not provide protection against Adriamycin toxicity and 500 fold elevation even
enhances the Adriamycin cardiotoxicity. The same observation has also been reported
in vitro. For instance, transfection of L cells with a human catalase cDNA elevated
catalase activity by 100-fold. These catalase-enriched cells, however, were more
sensitive rather than resistant to the cytotoxicity of paraquat, bleomycin, and
Adriamycin than the untransfected cells from which they were derived (45). At least
two mechanisms have been proposed for the increased sensitivity of the high catalase
containing cells: (1) imbalance between SOD and catalase (46-48); (2) chelation of
heme iron by catalase and release of iron after degradation of catalase. It has been
shown that iron-Adriamycin complex is toxic (49). The relevant mechanism for the
effect observed in our mice is unknown. Therefore, we will determine why the very
high level of cardiac catalase does not provide protection against, or even enhances
Adriamycin cardiotoxicity.
Both catalase and GSHpx are important in detoxification of H20 2. GSHpx is
also capable of reducing organic hydroperoxides. The importance of catalase in
providing protection against extra-peroxisomal H20 2 is not clear. Studies with isolated
hepatocytes, however, have demonstrated that under conditions of GSH depletion
139
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catalase functions in metabolism of H20 2 produced by the cytochrome P-450-linked
monooxygenase system [11]. It is thus possible that under conditions of extreme
oxidative stress, which in most cases involves GSH depletion, catalase may become
increasingly important in providing protection against xenobiotic-induced H2Oz
production. In future, we will determine whether the elevated catalase activity can
replace the role of GSHpx in cellular defense against oxidative stress and Adriamycininduced injury by using both primary cell cultures and whole animal studies.
As mentioned in the introduction, catalase is localized mostly within the
peroxisomal compartment. At present, we do not know whether the transgene-directed
expression of catalase activity is targeted to the peroxisome, cytosol, or other
compartments. It is worthwhile to determine the localization of the overexpressed
catalase activity in the cell. Similarly, it is important to know which cell types in the
heart are targeted to express the transgenic catalase. Polyclonal antibody to catalase is
commercially available. Therefore we will use light-microscopic immunoperoxidase
and electron-microscopic immunogold techniques to identify both the cell types to
which the catalase is expressed and the subcellular localization of the catalase in the
myocardium tissue. The significance of subcellular localization and the cell type of
expression of the catalase in the protective response to Adriamycin will thus be
elucidated.

APPENDIX
ADP

Adenosine 5'-diphosphate

ADR

Adriamycin

ATP

Adenosine 5'-triphosphate

CPK

creatine phosphokinase

DTNB

5,5'-dithiobis (2-nitrobenzoate)

EDTA

ethylenediaminotetraacetic acid

g

grams

GR

glutathione reductase

GSH

glutathione (reduced form)

GSHpx

glutathione peroxidase

GSSG

glutathione disulfide

1

liter

M

Molar

mg

milligrams

min

minutes

ml

milliliter

mM

millimolar

mol

mole

141

142

mmol

millimole

MT

metallothionein

NAD, NADH

Nicotinamide adenine dinucleotide and the reduced form

NADP, NADPH

Nicotinamide adenine dinucleotide phosphate and the reduced
form

nM

nanomolar

nmol

nanomole

PCR

Polymerase chain reaction

SDS

sodium dodecyl sulfate

sec

seconds

SOD

superoxide dismutase

rpm

revolutions per minute

Tris

tris hydroxymethylaminomethane

Pg

microgram

Pi

microliter

pM

micromolar

pmol

micromole
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